Professor Martin Stockler
NHMRC Clinical Trials Centre
Medicine, Central Clinical School
Martin Stockleris Professor of Oncology and Clinical Epidemiology at The University of Sydney, a consultant medical oncologist at the Concord Repatriation General Hospital and Chris O’Brien Lifehouse RPA, and Oncology Director at the NHMRC Clinical Trials Centre.
After internal medicine and medical oncology training in Sydney, Australia he spent 3 years in Toronto, Canada doing a clinical research fellowship at the Princess Margaret Hospital and a Masters in Clinical Epidemiology at the University of Toronto with Ian Tannock and Pamela Goodwin.
His research focuses on using clinical trials to improve quality of life, survival, prognostication, and doctor-patient communication for those affected by cancer, particularly from genitourinary, gynaecologic and thoracic primaries. His clinical focus is genitourinary cancers.
Improving quality of life, survival, prognostication, and doctor-patient communication for those affected by cancer, particularly genitourinary (prostate, testis, kidney, bladder), gynaecologic (ovary, endometrium, cervix), and thoracic (lung and mesothelioma). Clinical trials, meta-analaysis, evidence based medicine, biostatistics.
Oncology, clinical research methods, evidence-based medicine, patient-doctor communication.
Selected publications
(Sydney University Press, 2010)
Publications
Books
- Chapman, S., Barratt, A., Stockler, M. (2010). Let sleeping dogs lie What men should know before getting tested for prostate cancer. Sydney: Sydney University Press.
Book Chapters
- Butow, P., Tattersall, M., Stockler, M. (2017). Discussing prognosis and communicating risk. In D. Kissane, B. Bultz, P. Butow, C. Bylund, S. Noble & S. Wilkinson (Eds.), Oxford Textbook of Communication in Oncology and Palliative Care (Second Edition), (pp. 77-82). Oxford: Oxford University Press. [More Information]
- Butow, P., Hagerty, R., Tattersall, M., Stockler, M. (2008). Foretelling: Communicating the prognosis. In N. Christakis and P. Glare (Eds.), Prognosis in Advanced Cancer, (pp. 33-53). Oxford: Oxford University Press.
- Stockler, M., Duric, V., Coates, A. (2006). Patients' preferences: what makes treatments worthwhile? In Martine J. Piccart .. [et al.] (Eds.), Breast cancer and molecular medicine, (pp. 925-944). Berlin ; New York: Springer.
Journals
- Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
- Mahon, K., De Bono, J., Chi, K., Clark, G., Breit, S., Brown, D., Horvath, L., Sutherland, S., Lin, H., Stockler, M., Gurney, H., et al (2024). Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. The Prostate, 84(8), 747-755. [More Information]
- Naher, S., Mercieca-Bebber, R., Siu, D., Stockler, M., Kiely, B., Grimison, P. (2024). Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials. Current Medical Research and Opinion. [More Information]
- Hofman, M., Kirkwood, I., Ng, S., Francis, R., Gedye, C., Rutherford, N., Weickhardt, A., Scott, A., Lee, S., Kwan, E., Guminski, A., Hsiao, E., Zhang, A., Stockler, M., Martin, A., et al (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25(1), 99-107. [More Information]
- Subramaniam, S., Adams, D., Tognela, A., Roncolato, F., Yip, P., Lim, S., Roohullah, A., Stockler, M., Kiely, B. (2024). Patients' perception of the benefits of palliative systemic therapy for advanced cancer. Internal Medicine Journal. [More Information]
- Sharifi, N., Portman, N., Davis, I., Sweeney, C., Diaz, R., Lin, H., Roberts, E., Horvath, L., Martin, A., Stockler, M., Yip, S., et al (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. Journal of Clinical Investigation, 134(18), e183583. [More Information]
- Nahm, S., Subramaniam, S., Stockler, M., Kiely, B. (2024). Timing of prognostic discussions in people with advanced cancer: a systematic review. Supportive Care in Cancer, 32(2), 127. [More Information]
- Campbell, I., Wetzig, N., Ung, O., Espinoza, D., Farshid, G., Collins, J., Kollias, J., Gebski, V., Mister, R., Simes, R., Stockler, M., et al (2023). 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. Breast, 70, 70-75. [More Information]
- John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A., Wilson, P., Niman, R., Ayers, M., Poole, A., Stockler, M., et al (2023). 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. Journal of Nuclear Medicine, 64(3), 410-415. [More Information]
- Nahm, S., Martin, A., Clayton, J., Grimison, P., Moth, E., Pavlakis, N., Sjoquist, K., Smith-Uffen, M., Tognela, A., Vasista, A., Stockler, M., Kiely, B. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7(6). [More Information]
- Mileshkin, L., Moore, K., Barnes, E., Gebski, V., Narayan, K., King, M., Bradshaw, N., Lee, C., Diamante, K., Fyles, A., Stockler, M., et al (2023). Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(5), 468-482. [More Information]
- Yabroff, K., Boehm, A., Nogueira, L., Sherman, M., Bradley, C., Shih, Y., Keating, N., Gomez, S., Banegas, M., Ambs, S., Stockler, M., et al (2023). An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. Journal of the National Cancer Institute, 115(10), 1115-1120. [More Information]
- Pathmanandavel, S., Crumbaker, M., Ho, B., Yam, A., Ayers, M., Sharma, S., Hickey, A., Eu, P., Stockler, M., Martin, A., et al (2023). Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of Nuclear Medicine, 64(2), 221-226. [More Information]
- Hayes, S., Obermair, A., Mileshkin, L., Davis, A., Gordon, L., Eakin, E., Janda, M., Beesley, V., Barnes, E., Spence, R., Andrews, J., Brand, A., Lee, C., Stockler, M., et al (2023). Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. BMJ Open, 13(4), e067925. [More Information]
- Campbell, R., King, M., Stockler, M., Lee, C., Roncolato, F., Friedlander, M. (2023). Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice. Patient Related Outcome Measures, 14, 111-126. [More Information]
- Conduit, C., Bastick, P., Campbell, D., Hansen, A., Leonard, M., McJannett, M., Stockler, M., Gibbs, P., Toner, G., Davis, I., Grimison, P., et al (2023). Patterns of Relapse in Australian Patients with Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice, 19(11), 973-980. [More Information]
- Livingstone (nee Ratcliffe), A., Howard, K., Menzies, A., Long, G., Stockler, M., Morton, R. (2023). Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma - A Discrete Choice Experiment. The Patient, 16(5), 497-513. [More Information]
- Naher, S., Mercieca-Bebber, R., Siu, D., Grimison, P., Stockler, M. (2023). Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review. Internal Medicine Journal, 53(11), 1946-1955. [More Information]
- Smith, D., Robledo, K., Yip, S., Parry, M., Kok, P., Lee, C., Friedlander, M., Baron-Hay, S., Shannon, C., Coward, J., Andrews, J., Stockler, M., et al (2023). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers, 15(1). [More Information]
- Sweeney, C., Martin, A., Stockler, M., Begbie, S., Cheung, L., Chi, K., Chowdhury, S., Frydenberg, M., Horvath, L., Joshua, A., Winter, D., Yip, S., Zhang, A., et al (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(4), 323-334. [More Information]
- Pathmanandavel, S., Crumbaker, M., Nguyen, A., Yam, A., Ayers, M., Sharma, S., Eu, P., Martin, A., Stockler, M., Joshua, A., et al (2023). The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). Journal of Nuclear Medicine, 64(1), 69-74. [More Information]
- Sjoquist, K., Martin, A., Pavlakis, N., Goldstein, D., Tsobanis, E., Moses, D., Maher, R., Hague, W., Gebski, V., Stockler, M., Simes, R. (2023). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. Journal of Cancer Research and Clinical Oncology, 149, 4959-4965. [More Information]
- Leighl, N., Laurie, S., Goss, G., Hughes, B., Stockler, M., Tsao, M., Hwang, D., Joubert, P., Kulkarni, S., Blais, N., et al (2022). CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 17(3), 434-445. [More Information]
- Farrell, R., Burling, M., Lee, C., Pather, S., Robledo, K., Mercieca-Bebber, R., Stockler, M. (2022). Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). Journal of Gynecologic Oncology, 33(1), e1. [More Information]
- Mak, B., Lin, H., Kwan, E., Fettke, H., Tran, B., Davis, I., Mahon, K., Stockler, M., Briscoe, K., Marx, G., Hoy, A., Horvath, L., et al (2022). Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 20(1), 112-1-112-14. [More Information]
- Agarwal, A., Karikios, D., Stockler, M., Morton, R. (2022). Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia. PloS One, 17(10 October). [More Information]
- Moth, E., Stockler, M., Kiely, B. (2022). Estimating prognosis in advanced cancer: Time to embrace uncertainty. Journal of Geriatric Oncology, 13(3), 389-390. [More Information]
- Oza, B., Eisen, T., Frangou, E., Stewart, G., Bex, A., Ritchie, A., Kaplan, R., Smith, B., Davis, I., Stockler, M., et al (2022). External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 40(16), 1772-1782. [More Information]
- Stockler, M., Martin, A., Davis, I., Dhillon, H., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Winter, D., Yip, S., et al (2022). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. Journal of Clinical Oncology, 40(8), 837-846. [More Information]
- Campbell, R., Costa, D., Stockler, M., Lee, C., Ledermann, J., Berton, D., Sehouli, J., Roncolato, F., O'Connell, R., Okamoto, A., Diamante, K., King, M., et al (2022). Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecologic Oncology, 166(2), 254-262. [More Information]
- Mak, B., Lin, H., Duong, T., Mahon, K., Joshua, A., Stockler, M., Gurney, H., Parnis, F., Zhang, A., Scheinberg, T., Hoy, A., Horvath, L., et al (2022). Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. Cancers, 14(19). [More Information]
- Zomerdijk, N., Panozzo, S., Mileshkin, L., Yoong, J., Nowak, A., Stockler, M., Philip, J. (2022). Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. European Journal of Cancer Care, 31(6). [More Information]
- Kok, P., Forde, P., Hughes, B., Sun, Z., Brown, C., Ramalingam, S., Cook, A., Lesterhuis, W., Yip, S., O'Byrne, K., Pavlakis, N., Ford, K., Parry, M., Stockler, M., et al (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12(1), e057663-1-e057663-8. [More Information]
- Buteau, J., Martin, A., Emmett, L., Iravani, A., Sandhu, S., Joshua, A., Francis, R., Zhang, A., Scott, A., Lee, S., Stockler, M., et al (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23(11), 1389-1397. [More Information]
- Stockler, M., Martin, A., Dhillon, H., Davis, I., Sweeney, C. (2022). Reply to L. Marandino et al. Journal of Clinical Oncology, 40(19), 2176-2177. [More Information]
- Lee, C., King, M., O'Connell, R., Lanceley, A., Joly, F., Hilpert, F., Davis, A., Roncolato, F., Okamoto, A., Bryce, J., Diamante, K., Stockler, M., et al (2022). Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study. International Journal of Gynecological Cancer. [More Information]
- Nahm, S., Stockler, M., Martin, A., Grimison, P., Fox, P., Zielinski, R., Hawson, G., Tattersall, M., Kiely, B. (2022). Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. Supportive Care in Cancer, 30(9), 7763-7772. [More Information]
- Hofman, M., Emmett, L., Sandhu, S., Iravani, A., Joshua, A., Goh, J., Pattison, D., Tan, T., Kirkwood, I., Ng, S., Guminski, A., Zhang, A., Stockler, M., Martin, A., et al (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397(10276), 797-804. [More Information]
- Mitchell, P., O'Byrne, K., Stockler, M., Yip, S., nhmrWalker, M., Balasubramaniam, S., Ab Rahman, A., Kok, P., Jurkovic, H., Brown, C., et al (2021). A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). International Journal of Radiation Oncology Biology Physics, 111(3), S10-S11. [More Information]
- Livingstone (nee Ratcliffe), A., Dempsey, K., Stockler, M., Howard, K., Long, G., Carlino, M., Menzies, A., Morton, R. (2021). Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. BMC Cancer, 21(1), 1014. [More Information]
- Rincones, O., Smith, A., Naher, S., Mercieca-Bebber, R., Stockler, M. (2021). An Updated Systematic Review of Quantitative Studies Assessing Anxiety, Depression, Fear of Cancer Recurrence or Psychological Distress in Testicular Cancer Survivors. Cancer Management and Research, 13, 3803-3816. [More Information]
- Antill, Y., Kok, P., Robledo, K., Yip, S., Parry, M., Smith, D., Spurdle, A., Barnes, E., Lee, C., Friedlander, M., Andrews, J., Stockler, M., et al (2021). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for ImmunoTherapy of Cancer, 9(6), 2255. [More Information]
- Emmett, L., Balasubramaniam, S., Joshua, A., Crumbaker, M., Martin, A., Zhang, A., Rana, N., Langford, A., Mitchell, J., Yip, S., Stockler, M., et al (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128(5), 642-651. [More Information]
- Scheinberg, T., Goodwin, A., Ip, E., Linton, A., Mak, B., Smith, D., Stockler, M., Strach, M., Tran, B., Young, A., Zhang, A., Mahon, K., Horvath, L. (2021). Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. JCO Oncology Practice, 17(2), e204-e216. [More Information]
- Sweeney, C., Martin, A., Stockler, M., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Horvath, L., Joshua, A., Marx, G., McJannett, M., Tu, E., Yip, S., Zhang, A., et al (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80(3), 275-279. [More Information]
- Lin, H., Mak, B., Yeung, N., Huynh, K., Meikle, T., Mellett, N., Kwan, E., Fettke, H., Tran, B., Davis, I., Mahon, K., Zhang, A., Stockler, M., Marx, G., Stricker, P., Scheinberg, T., Bonnitcha, P., Sullivan, D., Joshua, A., Horvath, L., et al (2021). Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 72, 103625. [More Information]
- Mercieca-Bebber, R., Naher, S., Rincones, O., Smith, A., Stockler, M. (2021). Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review. Patient Related Outcome Measures, 12, 129-171. [More Information]
- Blinman, P., Martin, A., Jefford, M., Goldstein, D., Boadle, D., Morris, M., Tebbutt, N., Aiken, C., Harkin, A., Segelov, E., Stockler, M., et al (2021). Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum, 5(1), pkaa107. [More Information]
- Agarwal, A., Livingstone (nee Ratcliffe), A., Karikios, D., Stockler, M., Beale, P., Morton, R. (2021). Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines. BMC Cancer, 21(1), 1036. [More Information]
- Meade, A., Oza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R., Choodari-Oskooei, B., Powles, T., Stewart, G., Albiges, L., Stockler, M., et al (2021). RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemporary Clinical Trials, 108, 106481. [More Information]
- Oza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R., Choodari-Oskooei, B., Powles, T., Stewart, G., Albiges, L., Bex, A., Stockler, M., et al (2021). RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemporary Clinical Trials, 108, 106482. [More Information]
- Lin, H., Yeung, N., Hastings, J., Croucher, D., Huynh, K., Meikle, T., Mellett, N., Kwan, E., Davis, I., Tran, B., Mahon, K., Zhang, A., Stockler, M., Horvath, L., et al (2021). Relationship between circulating lipids and cytokines in metastatic castration-resistant prostate cancer. Cancers, 13(19), 4964. [More Information]
- Livingstone (nee Ratcliffe), A., Milne, D., Dempsey, K., Muscat, D., Menzies, A., Howard, K., Stockler, M., Morton, R. (2021). Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. The Patient, 14(5), 635-647. [More Information]
- Ranganathan, P., Chinnaswamy, G., Sengar, M., Gadgil, D., Thiagarajan, S., Bhargava, B., Booth, C., Buyse, M., Chopra, S., Frampton, C., Stockler, M., et al (2021). The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. The Lancet Oncology, 22(8), e369-e376. [More Information]
- Eisen, T., Frangou, E., Oza, B., Ritchie, A., Smith, B., Kaplan, R., Davis, I., Stockler, M., Albiges, L., Escudier, B., et al (2020). Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: Results from the SORCE randomized phase III intergroup trial. Journal of Clinical Oncology, 38(34), 4064-4075. [More Information]
- Stockler, M. (2020). ASCO updated recommendations for preventing and treating VTE in adults with cancer. Annals of Internal Medicine, 172(2), JC2. [More Information]
- Vasista, A., Stockler, M., Martin, A., Lawrence, N., Kiely, B. (2020). Communicating prognostic information: what do oncologists think patients with incurable cancer should be told? Internal Medicine Journal, 50(12), 1492-1499. [More Information]
- Nowak, A., Lesterhuis, W., Kok, P., Brown, C., Hughes, B., Karikios, D., John, T., Kao, S., Leslie, C., Cook, A., Langford, A., Yip, S., Stockler, M., et al (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21(9), 1213-1223. [More Information]
- Sridhar, S., Blais, N., Tran, B., Reaume, M., North, S., Stockler, M., Chi, K., Fleshner, N., Liu, G., Robinson, J., et al (2020). Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients with Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. JAMA Oncology, 6(11), 1751-1758. [More Information]
- Smith-Uffen, M., Johnson, S., Martin, A., Tattersall, M., Stockler, M., Bell, M., Detering, K., Clayton, J., Silvester, W., Clarke, S., Vaccaro, L., Beale, P., Kiely, B. (2020). Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. Supportive Care in Cancer, 28(7), 3399-3407. [More Information]
- Moth, E., Blinman, P., Stefanic, N., Naganathan, V., Grimison, P., Stockler, M., Beale, P., Martin, A., Kiely, B. (2020). Estimating survival time in older adults receiving chemotherapy for advanced cancer. Journal of Geriatric Oncology, 11(4), 617-625. [More Information]
- Cohen, P., Leung, Y., Anderson, L., Van Der Griend, R., Chivers, P., Bilic, S., Bittinger, S., Brand, A., Bulsara, M., Codde, J., Stockler, M., et al (2020). Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy. Gynecologic Oncology, 159(3), 623-629. [More Information]
- Lawrence, N., Martin, A., Davis, I., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Smith, B., Ritchie, A., Stockler, M., et al (2020). Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 4(4), 185-195. [More Information]
- Grimison, P., Mersiades, T., Kirby, A., Lintzeris, N., Morton, R., Haber, P., Olver, I., Walsh, A., McGregor, I., Cheung, Y., Simes, R., Stockler, M., et al (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology, 31(11), 1553-1560. [More Information]
- Mercieca-Bebber, R., Stockler, M. (2020). Patient-reported outcomes and localized prostate cancer management. Nature Reviews Urology, 17(5), 257-258. [More Information]
- Scheinberg, T., Kench, J., Stockler, M., Mahon, K., Sebastian, L., Stricker, P., Joshua, A., Woo, H., Thanigasalam, R., Ahmadi, N., Horvath, L., et al (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), e033667. [More Information]
- Roncolato, F., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Salutari, V., Donnellan, P., Stockler, M., King, M., et al (2020). Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>= 3) chemotherapy - The GCIG symptom benefit study (SBS). Gynecologic Oncology, 156(1), 45-53. [More Information]
- Livingstone (nee Ratcliffe), A., Agarwal, A., Stockler, M., Menzies, A., Howard, K., Morton, R. (2020). Preferences for Immunotherapy in Melanoma: A Systematic Review. Annals of Surgical Oncology, 27(2), 571-584. [More Information]
- Vasista, A., Ryan, L., Naher, S., Moylan, E., Stockler, M., Wilcken, N., Kiely, B. (2020). Survival and cardiac toxicity in patients with HER2-positive, metastatic breast cancer treated with trastuzumab in routine clinical practice. Asia-Pacific Journal of Clinical Oncology, 16(1), 34-38. [More Information]
- Nowak, A., Findlay, M., Culjak, G., Stockler, M. (2020). Tamoxifen for hepatocellular carcinoma. Cochrane Database of Systematic Reviews, 2020 (8), CD001024. [More Information]
- Whitford, H., Kalinowski, P., Schembri, A., Grimison, P., Stockler, M., Martin, A., Toner, G., Davis, I., Maruff, P., Olver, I. (2020). The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. Supportive Care in Cancer, 28(7), 3081-3091. [More Information]
- Lee, K., Lord, S., Kasherman, L., Marschner, I., Stockler, M., Gralla, R., Yang, J., Mok, T., Lee, C. (2020). The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncologica, 59(1), 96-100. [More Information]
- Kiely, B., Stockler, M. (2020). When Should Oncologists Use the Words Hope and Cure? JNCI Cancer Spectrum, 4(6), pkaa066. [More Information]
- Kiely, B., Stockler, M. (2019). Accentuating the Positive: Do Trials Give Unrealistic Expectations of Long-Term Survival? JNCI Cancer Spectrum, 3(2), 1-2. [More Information]
- Vasista, A., Stockler, M., Martin, A., Pavlakis, N., Sjoquist, K., Goldstein, D., Gill, S., Jain, V., Liu, G., Kannourakis, G., Kiely, B., et al (2019). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. The Oncologist, 24(11), e1102-e1107. [More Information]
- Chim, L., Salkeld, G., Kelly, P., Lipworth, W., Hughes, D., Stockler, M. (2019). Community views on factors affecting medicines resource allocation: Cross-sectional survey of 3080 adults in Australia. Australian Health Review, 43(3), 254-260. [More Information]
- Kiely, B., Stockler, M. (2019). Discussing Prognosis, Preferences, and End-of-Life Care in Advanced Cancer: We Need to Speak. JAMA Oncology, 5(6), 788-789. [More Information]
- Davis, I., Stockler, M., Sweeney, C. (2019). Enzalutamide in Metastatic Prostate Cancer Reply. New England Journal of Medicine, 381(15), 1494-1495. [More Information]
- Davis, I., Martin, A., Stockler, M., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Horvath, L., Marx, G., Tu, E., Yip, S., Zhang, A., et al (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131. [More Information]
- Mersiades, T., Stockler, M., Olver, I., Grimison, P. (2019). Medicinal cannabis for chemotherapy-induced nausea and vomiting: prescribing with limited evidence. Medical Journal of Australia, 210(1), 11-1.20E+02. [More Information]
- Moth, E., Kiely, B., Stefanic, N., Naganathan, V., Martin, A., Grimison, P., Stockler, M., Beale, P., Blinman, P. (2019). Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. Journal of Geriatric Oncology, 10(2), 210-215. [More Information]
- Morgans, A., Stockler, M. (2019). Patient-reported Outcomes in Metastatic Castration-sensitive Prostate Cancer in the Adjuvant Setting. European Urology Focus, 5(2), 144-146. [More Information]
- Lindemann, K., Beale, P., Rossi, E., Goh, J., Vaughan, M., Tenney, M., Martyn, J., Sommeijer, D., Iglesias, J., Kremmidiotis, G., et al (2019). Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). Cancer Chemotherapy and Pharmacology, 83(1), 97-105. [More Information]
- Moth, E., Kiely, B., Stefanic, N., Naganathan, V., Martin, A., Grimison, P., Stockler, M., Beale, P., Blinman, P. (2019). Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. Journal of Geriatric Oncology, 10(2), 202-209. [More Information]
- Mahon, K., Qu, W., Lin, H., Spielman, C., Cain, D., Jacobs, C., Stockler, M., Higano, C., de Bono, J., Chi, K., Horvath, L., et al (2019). Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. European Urology, 76(3), 306-312. [More Information]
- Hofman, M., Emmett, L., Violet, J., Zhang, A., Lawrence, N., Stockler, M., Francis, R., Iravani, A., Williams, S., Azad, A., Martin, A., et al (2019). TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU International, 124(S1), 5-13. [More Information]
- Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Tattersall, M., et al (2018). A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. British Journal of Cancer, 119(10), 1182-1190. [More Information]
- Tran, A., Fogarty, G., Nowak, A., Espinoza, D., Rowbotham, N., Stockler, M., Morton, R. (2018). A systematic review and meta-analysis of utility estimates in melanoma. British Journal of Dermatology, 178(2), 384-393. [More Information]
- Smith, B., Rutherford, C., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G., Stockler, M., King, M. (2018). A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psycho-Oncology, 27(4), 1129-1137. [More Information]
- Zhang, A., Judson, I., Benson, C., Wunder, J., Ray-Coquard, I., Grimer, R., Quek, R., Wong, E., Miah, A., Ferguson, P., Stockler, M., Tattersall, M., et al (2018). Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. British Journal of Cancer, 117, 326-331. [More Information]
- Stockler, M., Wilcken, N., Coates, A., Ghersi, D. (2018). Duration of chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, 2018 (2). [More Information]
- Lawrence, N., Roncolato, F., Martin, A., Simes, R., Stockler, M. (2018). Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer. JNCI Cancer Spectrum, 2(4). [More Information]
- King, M., Stockler, M., O'Connell, R., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Bryce, J., Costa, D., et al (2018). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 27(1), 59-74. [More Information]
- Mersiades, T., Tognela, A., Haber, P., Stockler, M., Lintzeris, N., Simes, R., McGregor, I., Olver, I., Allsop, D., Gedye, C., Kirby, A., Morton, R., Wong, N., Walsh, A., Grimison, P., et al (2018). Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 8(9), 1-8. [More Information]
- Blinman, P., Davis, I., Martin, A., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., et al (2018). Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Annals of Oncology, 29(2), 370-376. [More Information]
- Stockler, M. (2018). Pooled RCTs: Reanalysis accounting for screening intensity suggests that screening reduces prostate cancer mortality. Annals of Internal Medicine, 168(2), JC5. [More Information]
- Lawrence, N., Chan, H., Toner, G., Stockler, M., Martin, A., Yip, S., Wong, N., Yeung, A., Mazhar, D., Pashankar, F., et al (2018). Protocol for the P3BEP trial (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer, 18(1), 1-6. [More Information]
- Wong, S., North, S., Sweeney, C., Stockler, M., Sridhar, S. (2018). Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 16(1), e233-e242. [More Information]
- Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., Simes, R., Stockler, M., Morton, R. (2018). Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics, 36(1), 67-78. [More Information]
- Mercieca-Bebber, R., Calvert, M., Kyte, D., Stockler, M., King, M. (2018). The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. Contemporary Clinical Trials Communications, 9, 23-32. [More Information]
- Mercieca-Bebber, R., King, M., Calvert, M., Stockler, M., Friedlander, M. (2018). The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Measures, 9, 353-367. [More Information]
- Roncolato, F., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., Okamoto, A., Aotani, E., Lorusso, D., Donnellan, P., Stockler, M., King, M., et al (2018). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 148(1), 36-41. [More Information]
- Lawrence, N., Martin, A., Davis, I., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Smith, B., Ritchie, A., Stockler, M., et al (2018). What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. Kidney Cancer, 2(2), 123-131. [More Information]
- Lin, H., Mahon, K., Weir, J., Mundra, P., Spielman, C., Briscoe, K., Gurney, H., Mallesara, G., Marx, G., Stockler, M., Hoy, A., Horvath, L., et al (2017). A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. International Journal of Cancer, 141(10), 2112-2120. [More Information]
- Mercieca-Bebber, R., Friedlander, M., Calvert, M., Stockler, M., Kyte, D., Kok, P., King, M. (2017). A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. Journal of Patient-Reported Outcomes, 1, 1-10. [More Information]
- Sundaresan, P., King, M., Stockler, M., Costa, D., Milross, C. (2017). Barriers to radiotherapy utilization: Consumer perceptions of issues influencing radiotherapy-related decisions. Asia-Pacific Journal of Clinical Oncology, 13(5), e489-e496. [More Information]
- Hayne, D., Stockler, M., McCombie, S., Lawrence, N., Martin, A., Sengupta, S., Davis, I. (2017). BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned. BJU International, 119, 55-57. [More Information]
- O'Carrigan, B., Wong, M., Willson, M., Stockler, M., Pavlakis, N., Goodwin, A. (2017). Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews, 2017 (10), 1-210. [More Information]
- Zhang, A., Judson, I., Benson, C., Wunder, J., Ray-Coquard, I., Grimer, R., Quek, R., Wong, E., Miah, A., Ferguson, P., Stockler, M., Tattersall, M., et al (2017). Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. British Journal of Cancer, 117, 326-331. [More Information]
- Karikios, D., Mileshkin, L., Martin, A., Ferraro, D., Stockler, M. (2017). Discussing and prescribing expensive unfunded anticancer drugs in Australia. ESMO Open, 2(2), 1-7. [More Information]
- Heiniger, L., Smith, B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J., Price, M., McJannett, M., Tran, B., Stockler, M., Gurney, H., Butow, P. (2017). e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer. European Journal of Cancer Care, 26(6), e12698. [More Information]
- Lindemann, K., Kok, P., Stockler, M., Jaaback, K., Brand, A. (2017). Enhanced recovery after surgery for advanced ovarian cancer: A systematic review of interventions trialed. International Journal of Gynecological Cancer, 27(6), 1274-1282. [More Information]
- Lindemann, K., Kok, P., Stockler, M., Sykes, P., Brand, A. (2017). Enhanced recovery after surgery for suspected ovarian malignancy: A survey of perioperative practice among gynecologic oncologists in Australia and New Zealand to Inform a Clinical Trial. International Journal of Gynecological Cancer, 27(5), 1046-1050. [More Information]
- Mercieca-Bebber, R., Friedlander, M., Kok, P., Calvert, M., Kyte, D., Stockler, M., King, M. (2017). Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. Quality of Life Research, 26(8), 2249-2250. [More Information]
- Cohen, P., Brand, A., Sykes, P., Wrede, D., McNally, O., Eva, L., Rao, A., Campion, M., Stockler, M., Powell, A., et al (2017). Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open, 7(8), 1-9. [More Information]
- Duchesne, G., Woo, H., King, M., Bowe, S., Stockler, M., Ames, A., D’Este, C., Frydenberg, M., Loblaw, A., Malone, S., Turner, S., et al (2017). Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. The Lancet Oncology, 18(9), 1192-1201. [More Information]
- Karikios, D., Chim, L., Martin, A., Nagrial, A., Howard, K., Salkeld, G., Stockler, M. (2017). Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia. Internal Medicine Journal, 47(4), 400-407. [More Information]
- Chambers, S., Occhipinti, S., Foley, E., Clutton, S., Legg, M., Berry, M., Stockler, M., Frydenberg, M., Gardiner, R., Lepore, S., Smith, D., et al (2017). Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 35(3), 291-297. [More Information]
- Vasista, A., Stockler, M., West, T., Wilcken, N., Kiely, B. (2017). More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. The Breast, 31, 99-104. [More Information]
- Lin, H., Mahon, K., Spielman, C., Gurney, H., Mallesara, G., Stockler, M., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A., Horvath, L. (2017). Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 116(8), 1002-1011. [More Information]
- Roncolato, F., Gibbs, E., Lee, C., Asher, R., Davies, L., Gebski, V., Friedlander, M., Hilpert, F., Wenzel, L., Stockler, M., King, M., et al (2017). Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Annals of Oncology, 28(8), 1849-1855. [More Information]
- Roncolato, F., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Stockler, M., King, M., et al (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. The Oncologist, 22(9), 1117-1124. [More Information]
- Wetzig, N., Gill, P., Espinoza, D., Mister, R., Stockler, M., Gebski, V., Ung, O., Campbell, I., Simes, R. (2017). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. Annals of Surgical Oncology, 24(4), 1064-1070. [More Information]
- Chim, L., Salkeld, G., Kelly, P., Lipworth, W., Hughes, D., Stockler, M. (2017). Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. PloS One, 12(3), 1-24. [More Information]
- Johnson, S., Clayton, J., Butow, P., Silvester, W., Detering, K., Hall, J., Kiely, B., Cebon, J., Clarke, S., Bell, M., Stockler, M., Tattersall, M., et al (2016). Advance care planning in patients with incurable cancer: Study protocol for a randomised controlled trial. BMJ Open, 6(12), 1-10. [More Information]
- Dong, S., Butow, P., Agar, M., Lovell, M., Boyle, F., Stockler, M., Forster, B., Jaure, A. (2016). Clinicians' Perspectives on Managing Symptom Clusters in Advanced Cancer: A Semistructured Interview Study. Journal of Pain and Symptom Management, 51(4), 706-717.e5. [More Information]
- Mercieca-Bebber, R., Palmer, M., Brundage, M., Calvert, M., Stockler, M., King, M. (2016). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. BMJ Open, 6(6), 1-47. [More Information]
- Schofield, P., Stockler, M., Zannino, D., Tebbutt, N., Price, T., Simes, R., Wong, N., Pavlakis, N., Ransom, D., Moylan, E., Wilcken, N., et al (2016). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Supportive Care in Cancer, 24(1), 401-408. [More Information]
- Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Grimison, P., et al (2016). Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 27(12), 2302-2303. [More Information]
- Blinman, P., Mileshkin, L., Khaw, P., Goss, G., Johnson, C., Capp, A., Brooks, S., Wain, G., Kolodziej, I., Veillard, A., O'Connell, R., Stockler, M., et al (2016). Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115(10), 1179-1185. [More Information]
- Dong, S., Butow, P., Jaure, A., Agar, M., Boyle, F., Forster, B., Stockler, M., Lovell, M. (2016). Patients' experiences and perspectives of multiple concurrent symptoms in advanced cancer: a semi-structured interview study. Supportive Care in Cancer, 24(3), 1373-1386. [More Information]
- Moth, E., McLachlan, S., Veillard, A., Muljadi, N., Hudson, M., Stockler, M., Blinman, P. (2016). Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer. Lung Cancer, 95, 8-14. [More Information]
- Sundaresan, P., Milross, C., Stockler, M., Costa, D., King, M. (2016). Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issues. Quality of Life Research, 25(9), 2361-2366. [More Information]
- Roncolato, F., Chatfield, M., Houghton, B., Toner, G., Stockler, M., Thomson, D., Friedlander, M., Gurney, H., Rosenthal, M., Grimison, P. (2016). The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal, 46(8), 893-898. [More Information]
- Mercieca-Bebber, R., Friedlander, M., Kok, P., Calvert, M., Kyte, D., Stockler, M., King, M. (2016). The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (with Erratum). Quality of Life Research, 25(10), 2457-2465. [More Information]
- Smith, B., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Turner, S., Gurney, H., King, M., et al (2016). The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship, 10(2), 223-233. [More Information]
- Chambers, S., Foley, E., Clutton, S., McDowall, R., Occhipinti, S., Berry, M., Stockler, M., Lepore, S., Frydenberg, M., Gardiner, R., et al (2016). The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Quality of Life Research, 25(12), 3027-3035. [More Information]
- Duchesne, G., Woo, H., Bassett, J., Bowe, S., D'Este, C., Frydenberg, M., King, M., Ledwich, L., Loblaw, A., Malone, S., Stockler, M., et al (2016). Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. The Lancet Oncology, 17(6), 727-737. [More Information]
- Lawrence, N., Salkeld, G., Stockler, M., Karikios, D. (2016). Valuing the benefits of new anticancer drugs. Medical Journal of Australia, 204(11), 403-405. [More Information]
- Sundaresan, P., Stockler, M., Milross, C. (2016). What is access to radiation therapy? A conceptual framework and review of influencing factors. Australian Health Review, 40(1), 11-18. [More Information]
- Davidson, A., Veillard, A., Tognela, A., Chan, M., Huighes, B., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Chinchen, S., Espinoza, D., Coskinas, X., Pavlakis, N., Stockler, M., et al (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Annals of Oncology, 26(11), 2280-2286. [More Information]
- Sundaresan, P., King, M., Stockler, M., Costa, D., Milross, C. (2015). Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors. Journal of Medical Imaging and Radiation Oncology, 59(4), 535-541. [More Information]
- Hayne, D., Stockler, M., McCombie, S., Chalasani, V., Long, A., Martin, A., Sengupta, S., Davis, I. (2015). BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC Cancer, 15(1), 1-7. [More Information]
- Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British Journal of Cancer, 112(8), 1340-1348. [More Information]
- Juraskova, I., Butow, P., Fisher, A., Bonner, C., Anderson, C., Bu, S., Scarlet, J., Stockler, M., Wetzig, N., Ung, O., et al (2015). Development and piloting of a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 breast cancer trial. Clinical Trials, 12(4), 409-417. [More Information]
- Moth, E., Parry, J., Stockler, M., Beale, P., Blinman, P., Della Fiorentina, S., Kiely, B. (2015). Doctor to doctor communication of prognosis in metastatic cancer: a review of letters from medical oncologists to referring doctors. Internal Medicine Journal, 45(9), 909-915. [More Information]
- Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
- Elmadahm, A., Gill, P., Bochner, M., Gebski, V., Zannino, D., Wetzig, N., Campbell, I., Stockler, M., Ung, O., Simes, R., Uren, R. (2015). Identification of the sentinel lymph node in the SNAC-1 trial. ANZ Journal of Surgery, 85(1-2), 58-63. [More Information]
- Stockler, M. (2015). In palliative care, discontinuation of statins did not differ from continuation for mortality. Annals of Internal Medicine, 163(4), JC7-JC7. [More Information]
- Blinman, P., Hughes, B., Crombie, C., Christmas, T., Hudson, M., Veillard, A., Muljadi, N., Millward, M., Wright, G., Flynn, P., Stockler, M., et al (2015). Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile? European Journal of Cancer, 51(12), 1529-1537. [More Information]
- Sundaresan, P., Sullivan, L., Pendlebury, S., Kirby, A., Rodger, A., Joseph, D., Campbell, I., Dhillon, H., Stockler, M. (2015). Patients' Perceptions of Health-related Quality of Life During and After Adjuvant Radiotherapy for T1N0M0 Breast Cancer. Clinical Oncology, 27(1), 9-15. [More Information]
- Lyerley, H., Fawzy, M., Aziz, Z., Nair, R., Pramesh, C., Parmar, V., Parikh, P., Jamal, R., Irumnaz, A., Ren, J., Stockler, M., et al (2015). Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. The Oncologist, 20(5), 1-7. [More Information]
- Wetzig, N., Gill, P., Zannino, D., Stockler, M., Gebski, V., Ung, O., Campbell, I., Simes, R. (2015). Sentinel Lymph Node Based Management or Routine Axillary Clearance? Three-year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial. Annals of Surgical Oncology, 22(1), 17-23. [More Information]
- Sengupta, S., Grimison, P., Hayne, D., Williams, S., Chambers, S., de Souza, P., Stockler, M., McJannett, M., Toner, G., Davis, I. (2015). The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group - a new co-operative cancer trials group in genitourinary oncology. BJU International, 115(6), 856-858. [More Information]
- Chim, L., Salkeld, G., Stockler, M., Mileshkin, L. (2015). Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists. Internal Medicine Journal, 45(8), 834-842. [More Information]
- Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
- Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
- Ellis, P., Shepherd, F., Millward, M., Perrone, F., Seymour, L., Liu, G., Sun, S., Cho, B., Morabito, A., Leighl, N., Stockler, M., et al (2014). Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. The Lancet Oncology, 15(12), 1379-1388. [More Information]
- King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
- Tattersall, M., Martin, A., Devine, R., Ryan, J., Jansen, J., Hastings, L., Boyer, M., Glare, P., Stockler, M., Butow, P. (2014). Early Contact with Palliative Care Services: A Randomized Trial in Patients with Newly Detected Incurable Metastatic Cancer. Journal of Palliative Care & Medicine, 4(1), 1-6. [More Information]
- West, T., Kiely, B., Stockler, M. (2014). Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 50(11), 1916-1924. [More Information]
- Sundaresan, P., Milross, C., Smith, A., Evans, A., Stockler, M., King, M. (2014). Factors influencing the use of RT in NSW: A qualitative study exploring consumer and health professional perspectives. Journal of Medical Imaging and Radiation Oncology, 58(5), 625-632. [More Information]
- Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
- Goodwin, P., Bruera, E., Stockler, M. (2014). Pain in patients with cancer. Journal of Clinical Oncology, 32(16), 1637-1639. [More Information]
- Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1319. [More Information]
- Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Stockler, M., et al (2014). Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer, 50(4), 706-712. [More Information]
- Karikios, D., Schofield, D., Salkeld, G., Robledo, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
- Beumer, J., Gill, G., Campbell, I., Wetzig, N., Ung, O., Farshid, G., Uren, R., Stockler, M., Gebski, V. (2014). Sentinel node biopsy and large (3cm) breast cancer. ANZ Journal of Surgery, 84(3), 117-120. [More Information]
- Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]
- O'Carrigan, B., Fournier, M., Olver, I., Stockler, M., Whitford, H., Toner, G., Thomson, D., Davis, I., Hanning, F., Singhal, N., McDonald, A., Boland, A., Grimison, P., et al (2014). Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. Internal Medicine Journal, 44(8), 813-817. [More Information]
- Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
- McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
- Gzell, C., Kench, J., Stockler, M., Hruby, G. (2013). Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. International Urology and Nephrology, 45(3), 735-742. [More Information]
- Pavlakis, N., Patel, D., Stockler, M. (2013). Bisphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 2013 (6). [More Information]
- Friedlander, M., Stockler, M., Butow, P., King, M., McAlpine, J., Tinker, A., Ledermann, J. (2013). Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? Journal of Clinical Oncology, 31(18), 2362. [More Information]
- Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
- Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
- Stockler, M. (2013). Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Annals of Internal Medicine, 158(2), JC9. [More Information]
- Houghton, B., Chalasani, V., Hayne, D., Grimison, P., Brown, C., Patel, M., Davis, I., Stockler, M. (2013). Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 111(6), 977-933. [More Information]
- Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine, 16(8), 938-940. [More Information]
- Grimison, P., Houghton, B., Chatfield, M., Toner, G., Davis, I., Martin, J., Hovey, E., Stockler, M. (2013). Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 112(2), E35-E43. [More Information]
- Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
- Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
- Martin, A., Lord, S., Carter, H., Stockler, M., Emery, J. (2013). Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Medical Journal of Australia, 198(10), 546-550. [More Information]
- Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., et al (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology, 14(3), 236-243. [More Information]
- Thientosapol, E., Tran, T., Della Fiorentina, S., Adams, D., Chantrill, L., Stockler, M., Kiely, B. (2013). Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Internal Medicine Journal, 43(8), 883-888. [More Information]
- Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
- Smith, B., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology, 22(11), 2557-2564. [More Information]
- Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]
- Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
- Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
- Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444. [More Information]
- Kiely, B., Stockler, M. (2012). Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine, 156(6), JC3-4-JC3-4. [More Information]
- Blinman, P., King, M., Norman, R., Viney, R., Stockler, M. (2012). Preferences for cancer treatments: An overview of methods and applications in oncology. Annals of Oncology, 23(5), 1104-1110. [More Information]
- King, M., Viney, R., Smith, D., Hossain, I., Street, D., Savage, E., Fowler, S., Berry, M., Stockler, M., Cozzi, P., Armstrong, B., et al (2012). Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 106(4), 638-645. [More Information]
- Stockler, M., Wilcken, N. (2012). Why Is Management of Cancer Pain Still a Problem? Journal of Clinical Oncology, 30(16), 1907-1908. [More Information]
- Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
- Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
- Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]
- Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2011). How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 29(4), 456-463. [More Information]
- Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
- Blinman, P., McLachlan, S., Nowak, A., Duric, V., Brown, C., Wright, G., Millward, M., Fong, K., Stockler, M. (2011). Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), 213-218. [More Information]
- Lyerly, H., Abernethy, A., Stockler, M., Koczwara, B., Aziz, Z., Nair, R., Seymour, L. (2011). Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice, 7(5), 324-329. [More Information]
- Chen, J., Hruby, G., Stockler, M., Patanjali, N., Bucci, J., Perez, G., Loadsman, J., Sheehan, E. (2011). Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy, 10(6), 454-460. [More Information]
- Hruby, G., Chen, J., Bucci, J., Loadsman, J., Perry, P., Stockler, M. (2011). Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy, 10(5), 395-400. [More Information]
- Stockler, M. (2011). Quality of Life and Targeted Treatment for Metastatic Renal Cell Carcinoma. The Oncologist, 16(8), 1070-1071. [More Information]
- Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
- Ooi, W., Stockler, M., Hayne, D. (2011). Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993). European Urology, 60(1), e1-e8. [More Information]
- Kiely, B., Stockler, M., Tattersall, M. (2011). Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology, 38(3), 380-385. [More Information]
- Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
- Lovell, M., Forder, P., Stockler, M., Butow, P., Briganti, E., Chye, R., Goldstein, D., Boyle, F. (2010). A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. Journal of Pain and Symptom Management, 40(1), 49-59. [More Information]
- Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
- Chim, L., Kelly, P., Salkeld, G., Stockler, M. (2010). Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? PharmacoEconomics, 28(6), 463-475. [More Information]
- Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
- Kiely, B., Tattersall, M., Stockler, M. (2010). Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. Journal of Clinical Oncology, 28(16), 2802-2804. [More Information]
- Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
- Liu, S., Stockler, M., Lin, B. (2010). Five-Year Survival After Multimodal Approach in a Patient With Muscle-Invasive Transitional Cell Carcinoma of the Bladder and Adrenal Metastasis. UroToday International Journal, 3(5), 0.
- Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
- King, M., Stockler, M., Cella, D., Osoba, D., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. Journal of Clinical Epidemiology, 63(3), 270-281. [More Information]
- King, M., Cella, D., Osoba, D., Stockler, M., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Related Outcome Measures, 1, 119-126. [More Information]
- Blinman, P., Alam, M., Duric, V., McLachlan, S., Stockler, M. (2010). Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review. Lung Cancer, 69(2), 141-147. [More Information]
- Luckett, T., King, M., Stockler, M. (2010). Quality of life research in prostate and testicular cancer. Cancer Forum, 34(1), 20-23. [More Information]
- Tebbutt, N., Parry, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481. [More Information]
- Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
- Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
- Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
- Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
- Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. Value in Health, 12(6), 967-976. [More Information]
- Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
- Barratt, A., Stockler, M. (2009). Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 191(4), 226-229. [More Information]
- Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
- Stockler, M., March, L., Lindley, R., Mellis, C. (2009). Students' PEARLS: successfully incorporating evidence-based medicine in medical students' clinical attachments. Annals of Internal Medicine, 150(8), JC4-2-JC4-3. [More Information]
- Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]
- Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N. (2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 20(11), 1771-1785. [More Information]
- Greaves, J., Glare, P., Kristjanson, L., Stockler, M., Tattersall, M. (2009). Undertreatment of nausea and other symptoms in hospitalized cancer patients. Supportive Care in Cancer, 17(4), 461-464. [More Information]
- Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67. [More Information]
- Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, 117(1), 99-109. [More Information]
- Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
- Gainford, M., Yang, C., Liu, M., Stockler, M. (2008). Translation and cultural adaptation of the patient disease and treatment assessment form: A novel quality of life instrument for use in Taiwan. Asia-Pacific Journal of Clinical Oncology, 4(3), 149-156. [More Information]
- Lee, B., King, M., Simpson, J., Haran, M., Stockler, M., Marial, O., Salkeld, G. (2008). Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population. Value in Health, 11(4), 680-688. [More Information]
- Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
- Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
- Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8(7), 603-612. [More Information]
- Wilcken, N., Stockler, M. (2007). Ovarian suppression for early breast cancer. The Lancet, 369, 1668-1670. [More Information]
- Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology, 16(1), 48-59. [More Information]
- Grimison, P., Stockler, M. (2007). Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy, 7(8), 1123-1134. [More Information]
- Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N., et al (2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 18(2), 215-225. [More Information]
- Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
- Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
- Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
- Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
- Hauser, C., Stockler, M., Tattersall, M. (2006). Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supportive Care in Cancer, 14, 999-1011. [More Information]
- Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
- Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
- Stockler, M., Heritier, S., Nowak, A., Goldstein, D., Turner, J., Jefford, M., Glasgow, A., Abdi, E., Beale, P., Carter, C. (2006). The time taken to complete quality of life questionnaires in an advanced cancer trial. Journal of Clinical Oncology, 24(18S), 491s-491s.
- Koczwara, B., Tattersall, M., Barton, M., Coventry, B., Dewar, J., Millar, J., Olver, I., Schwarz, M., Starmer, D., Turner, D., Stockler, M. (2005). Achieving equal standards in medical student education: is a national exit examination the answer? Medical Journal of Australia, 182(5), 228-230. [More Information]
- Joshua, A., Celermajer, D., Stockler, M. (2005). Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. Internal Medicine Journal, 35(3), 178-187. [More Information]
- Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 0(3), CD003474. [More Information]
- Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
- Haran, M., Lee, B., King, M., Marial, O., Stockler, M. (2005). Health status rated with the Medical Outcomes Study 36-Item Short-Form Health Survey after spinal cord injury. Archives of Physical Medicine and Rehabilitation, 86(12), 2290-2295. [More Information]
- Medd, J., Stockler, M., Collins, R., Lalak, A. (2005). Measuring men's opinions of prostate needle biopsy. ANZ Journal of Surgery, 75(8), 662-664. [More Information]
- Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillett, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2005). Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ Journal of Surgery, 75(3), 98-100. [More Information]
- Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
- Duric, V., Fallowfield, L., Saunders, C., Houghton, J., Coates, A., Stockler, M. (2005). Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? British Journal of Cancer, 93(12), 1319-1323. [More Information]
- Stockler, M. (2005). Review: bisphosphonates are modestly better than placebo for relieving painful bone metastases. ACP Journal Club, 143(1), 13. [More Information]
- Nowak, A., Stockler, M., Chow, P., Findlay, M. (2005). Use of Tamoxifen in Advanced-Stage Hepatocellular Carcinoma. Cancer, 103(7), 1408-1414. [More Information]
- Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
- Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? The Lancet Oncology, 6(8), 581-588. [More Information]
- Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
- Stockler, M., Vardy, J., Pillai, A., Warr, D. (2004). Acetaminophen (Paracetamol) Improves Pain And Well-Being In People With Advanced Cancer Already Receiving A Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial. Journal of Clinical Oncology, 22(16), 3389-3394. [More Information]
- Nowak, A., Stockler, M., Byrne, M. (2004). Assessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172-3180. [More Information]
- Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049. [More Information]
- Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology, 22(14S), 73S-73S.
- Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71. [More Information]
- Nowak, A., Wilcken, N., Stockler, M., Hamilton, A., Ghersi, D. (2004). Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer. The Lancet Oncology, 5(6), 372-380. [More Information]
- Glare, P., Pereira, G., Kristjanson, L., Stockler, M., Tattersall, M. (2004). Systematic Review Of The Efficacy Of Antiemetics In The Treatment Of Nausea In Patients With Far-Advanced Cancer. Supportive Care in Cancer, 12(6), 432-440. [More Information]
- Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.
- Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
- Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.
- Wilcken, N., Stockler, M. (2003). Fulvestrant: spreading the word, but not too thinly. The Lancet, 362(9392), 1254-1254. [More Information]
- Jefford, M., Stockler, M., Tattersall, M. (2003). Outcomes research: what is it and why does it matter? Internal Medicine Journal, 33(3), 110-118. [More Information]
- Eckermann, S., Martin, A., Stockler, M., Simes, R. (2003). The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 27(1), 34-40. [More Information]
- Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17. [More Information]
- Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.
- Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83. [More Information]
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745. [More Information]
- Craig, J., Irwig, L., Stockler, M. (2001). Evidence-based medicine: useful tools for decision making. Medical Journal of Australia, 174, 248-253.
- Gooden, B., Smith, M., Tattersall, S., Stockler, M. (2001). Hospitalised patients' views on doctors and white coats. Medical Journal of Australia, 175, 219-222.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Duric, V., Stockler, M. (2001). Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile? The Lancet Oncology, 2(11), 691-697. [More Information]
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168. [More Information]
Conferences
- Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Beale, P., Fitzgerald, N., Tattersall, M. (2017). A Randomized Controlled Trial of an Advance Care Planning Intervention for Patients with Incurable Cancer. The 44th Clinical Oncological Society of Australia Annual Scientific Meeting,.
- Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
- Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
- Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.
- Craig, J., Irwig, L., Stockler, M., Barratt, A., Cumming, R., Caplehorn, J. (2001). Clinical epidemiology education: to help culture change now and generate new research later. 4th International Conference on the Scientific Basis of Health Services.
2024
- Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
- Mahon, K., De Bono, J., Chi, K., Clark, G., Breit, S., Brown, D., Horvath, L., Sutherland, S., Lin, H., Stockler, M., Gurney, H., et al (2024). Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. The Prostate, 84(8), 747-755. [More Information]
- Naher, S., Mercieca-Bebber, R., Siu, D., Stockler, M., Kiely, B., Grimison, P. (2024). Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials. Current Medical Research and Opinion. [More Information]
- Hofman, M., Kirkwood, I., Ng, S., Francis, R., Gedye, C., Rutherford, N., Weickhardt, A., Scott, A., Lee, S., Kwan, E., Guminski, A., Hsiao, E., Zhang, A., Stockler, M., Martin, A., et al (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25(1), 99-107. [More Information]
- Subramaniam, S., Adams, D., Tognela, A., Roncolato, F., Yip, P., Lim, S., Roohullah, A., Stockler, M., Kiely, B. (2024). Patients' perception of the benefits of palliative systemic therapy for advanced cancer. Internal Medicine Journal. [More Information]
- Sharifi, N., Portman, N., Davis, I., Sweeney, C., Diaz, R., Lin, H., Roberts, E., Horvath, L., Martin, A., Stockler, M., Yip, S., et al (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. Journal of Clinical Investigation, 134(18), e183583. [More Information]
- Nahm, S., Subramaniam, S., Stockler, M., Kiely, B. (2024). Timing of prognostic discussions in people with advanced cancer: a systematic review. Supportive Care in Cancer, 32(2), 127. [More Information]
2023
- Campbell, I., Wetzig, N., Ung, O., Espinoza, D., Farshid, G., Collins, J., Kollias, J., Gebski, V., Mister, R., Simes, R., Stockler, M., et al (2023). 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. Breast, 70, 70-75. [More Information]
- John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A., Wilson, P., Niman, R., Ayers, M., Poole, A., Stockler, M., et al (2023). 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. Journal of Nuclear Medicine, 64(3), 410-415. [More Information]
- Nahm, S., Martin, A., Clayton, J., Grimison, P., Moth, E., Pavlakis, N., Sjoquist, K., Smith-Uffen, M., Tognela, A., Vasista, A., Stockler, M., Kiely, B. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7(6). [More Information]
- Mileshkin, L., Moore, K., Barnes, E., Gebski, V., Narayan, K., King, M., Bradshaw, N., Lee, C., Diamante, K., Fyles, A., Stockler, M., et al (2023). Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(5), 468-482. [More Information]
- Yabroff, K., Boehm, A., Nogueira, L., Sherman, M., Bradley, C., Shih, Y., Keating, N., Gomez, S., Banegas, M., Ambs, S., Stockler, M., et al (2023). An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. Journal of the National Cancer Institute, 115(10), 1115-1120. [More Information]
- Pathmanandavel, S., Crumbaker, M., Ho, B., Yam, A., Ayers, M., Sharma, S., Hickey, A., Eu, P., Stockler, M., Martin, A., et al (2023). Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of Nuclear Medicine, 64(2), 221-226. [More Information]
- Hayes, S., Obermair, A., Mileshkin, L., Davis, A., Gordon, L., Eakin, E., Janda, M., Beesley, V., Barnes, E., Spence, R., Andrews, J., Brand, A., Lee, C., Stockler, M., et al (2023). Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. BMJ Open, 13(4), e067925. [More Information]
- Campbell, R., King, M., Stockler, M., Lee, C., Roncolato, F., Friedlander, M. (2023). Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice. Patient Related Outcome Measures, 14, 111-126. [More Information]
- Conduit, C., Bastick, P., Campbell, D., Hansen, A., Leonard, M., McJannett, M., Stockler, M., Gibbs, P., Toner, G., Davis, I., Grimison, P., et al (2023). Patterns of Relapse in Australian Patients with Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice, 19(11), 973-980. [More Information]
- Livingstone (nee Ratcliffe), A., Howard, K., Menzies, A., Long, G., Stockler, M., Morton, R. (2023). Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma - A Discrete Choice Experiment. The Patient, 16(5), 497-513. [More Information]
- Naher, S., Mercieca-Bebber, R., Siu, D., Grimison, P., Stockler, M. (2023). Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review. Internal Medicine Journal, 53(11), 1946-1955. [More Information]
- Smith, D., Robledo, K., Yip, S., Parry, M., Kok, P., Lee, C., Friedlander, M., Baron-Hay, S., Shannon, C., Coward, J., Andrews, J., Stockler, M., et al (2023). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers, 15(1). [More Information]
- Sweeney, C., Martin, A., Stockler, M., Begbie, S., Cheung, L., Chi, K., Chowdhury, S., Frydenberg, M., Horvath, L., Joshua, A., Winter, D., Yip, S., Zhang, A., et al (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(4), 323-334. [More Information]
- Pathmanandavel, S., Crumbaker, M., Nguyen, A., Yam, A., Ayers, M., Sharma, S., Eu, P., Martin, A., Stockler, M., Joshua, A., et al (2023). The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). Journal of Nuclear Medicine, 64(1), 69-74. [More Information]
- Sjoquist, K., Martin, A., Pavlakis, N., Goldstein, D., Tsobanis, E., Moses, D., Maher, R., Hague, W., Gebski, V., Stockler, M., Simes, R. (2023). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. Journal of Cancer Research and Clinical Oncology, 149, 4959-4965. [More Information]
2022
- Leighl, N., Laurie, S., Goss, G., Hughes, B., Stockler, M., Tsao, M., Hwang, D., Joubert, P., Kulkarni, S., Blais, N., et al (2022). CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 17(3), 434-445. [More Information]
- Farrell, R., Burling, M., Lee, C., Pather, S., Robledo, K., Mercieca-Bebber, R., Stockler, M. (2022). Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). Journal of Gynecologic Oncology, 33(1), e1. [More Information]
- Mak, B., Lin, H., Kwan, E., Fettke, H., Tran, B., Davis, I., Mahon, K., Stockler, M., Briscoe, K., Marx, G., Hoy, A., Horvath, L., et al (2022). Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 20(1), 112-1-112-14. [More Information]
- Agarwal, A., Karikios, D., Stockler, M., Morton, R. (2022). Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia. PloS One, 17(10 October). [More Information]
- Moth, E., Stockler, M., Kiely, B. (2022). Estimating prognosis in advanced cancer: Time to embrace uncertainty. Journal of Geriatric Oncology, 13(3), 389-390. [More Information]
- Oza, B., Eisen, T., Frangou, E., Stewart, G., Bex, A., Ritchie, A., Kaplan, R., Smith, B., Davis, I., Stockler, M., et al (2022). External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 40(16), 1772-1782. [More Information]
- Stockler, M., Martin, A., Davis, I., Dhillon, H., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Winter, D., Yip, S., et al (2022). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. Journal of Clinical Oncology, 40(8), 837-846. [More Information]
- Campbell, R., Costa, D., Stockler, M., Lee, C., Ledermann, J., Berton, D., Sehouli, J., Roncolato, F., O'Connell, R., Okamoto, A., Diamante, K., King, M., et al (2022). Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecologic Oncology, 166(2), 254-262. [More Information]
- Mak, B., Lin, H., Duong, T., Mahon, K., Joshua, A., Stockler, M., Gurney, H., Parnis, F., Zhang, A., Scheinberg, T., Hoy, A., Horvath, L., et al (2022). Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. Cancers, 14(19). [More Information]
- Zomerdijk, N., Panozzo, S., Mileshkin, L., Yoong, J., Nowak, A., Stockler, M., Philip, J. (2022). Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. European Journal of Cancer Care, 31(6). [More Information]
- Kok, P., Forde, P., Hughes, B., Sun, Z., Brown, C., Ramalingam, S., Cook, A., Lesterhuis, W., Yip, S., O'Byrne, K., Pavlakis, N., Ford, K., Parry, M., Stockler, M., et al (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12(1), e057663-1-e057663-8. [More Information]
- Buteau, J., Martin, A., Emmett, L., Iravani, A., Sandhu, S., Joshua, A., Francis, R., Zhang, A., Scott, A., Lee, S., Stockler, M., et al (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23(11), 1389-1397. [More Information]
- Stockler, M., Martin, A., Dhillon, H., Davis, I., Sweeney, C. (2022). Reply to L. Marandino et al. Journal of Clinical Oncology, 40(19), 2176-2177. [More Information]
- Lee, C., King, M., O'Connell, R., Lanceley, A., Joly, F., Hilpert, F., Davis, A., Roncolato, F., Okamoto, A., Bryce, J., Diamante, K., Stockler, M., et al (2022). Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study. International Journal of Gynecological Cancer. [More Information]
- Nahm, S., Stockler, M., Martin, A., Grimison, P., Fox, P., Zielinski, R., Hawson, G., Tattersall, M., Kiely, B. (2022). Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. Supportive Care in Cancer, 30(9), 7763-7772. [More Information]
2021
- Hofman, M., Emmett, L., Sandhu, S., Iravani, A., Joshua, A., Goh, J., Pattison, D., Tan, T., Kirkwood, I., Ng, S., Guminski, A., Zhang, A., Stockler, M., Martin, A., et al (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397(10276), 797-804. [More Information]
- Mitchell, P., O'Byrne, K., Stockler, M., Yip, S., nhmrWalker, M., Balasubramaniam, S., Ab Rahman, A., Kok, P., Jurkovic, H., Brown, C., et al (2021). A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). International Journal of Radiation Oncology Biology Physics, 111(3), S10-S11. [More Information]
- Livingstone (nee Ratcliffe), A., Dempsey, K., Stockler, M., Howard, K., Long, G., Carlino, M., Menzies, A., Morton, R. (2021). Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. BMC Cancer, 21(1), 1014. [More Information]
- Rincones, O., Smith, A., Naher, S., Mercieca-Bebber, R., Stockler, M. (2021). An Updated Systematic Review of Quantitative Studies Assessing Anxiety, Depression, Fear of Cancer Recurrence or Psychological Distress in Testicular Cancer Survivors. Cancer Management and Research, 13, 3803-3816. [More Information]
- Antill, Y., Kok, P., Robledo, K., Yip, S., Parry, M., Smith, D., Spurdle, A., Barnes, E., Lee, C., Friedlander, M., Andrews, J., Stockler, M., et al (2021). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for ImmunoTherapy of Cancer, 9(6), 2255. [More Information]
- Emmett, L., Balasubramaniam, S., Joshua, A., Crumbaker, M., Martin, A., Zhang, A., Rana, N., Langford, A., Mitchell, J., Yip, S., Stockler, M., et al (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128(5), 642-651. [More Information]
- Scheinberg, T., Goodwin, A., Ip, E., Linton, A., Mak, B., Smith, D., Stockler, M., Strach, M., Tran, B., Young, A., Zhang, A., Mahon, K., Horvath, L. (2021). Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. JCO Oncology Practice, 17(2), e204-e216. [More Information]
- Sweeney, C., Martin, A., Stockler, M., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Horvath, L., Joshua, A., Marx, G., McJannett, M., Tu, E., Yip, S., Zhang, A., et al (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80(3), 275-279. [More Information]
- Lin, H., Mak, B., Yeung, N., Huynh, K., Meikle, T., Mellett, N., Kwan, E., Fettke, H., Tran, B., Davis, I., Mahon, K., Zhang, A., Stockler, M., Marx, G., Stricker, P., Scheinberg, T., Bonnitcha, P., Sullivan, D., Joshua, A., Horvath, L., et al (2021). Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 72, 103625. [More Information]
- Mercieca-Bebber, R., Naher, S., Rincones, O., Smith, A., Stockler, M. (2021). Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review. Patient Related Outcome Measures, 12, 129-171. [More Information]
- Blinman, P., Martin, A., Jefford, M., Goldstein, D., Boadle, D., Morris, M., Tebbutt, N., Aiken, C., Harkin, A., Segelov, E., Stockler, M., et al (2021). Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum, 5(1), pkaa107. [More Information]
- Agarwal, A., Livingstone (nee Ratcliffe), A., Karikios, D., Stockler, M., Beale, P., Morton, R. (2021). Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines. BMC Cancer, 21(1), 1036. [More Information]
- Meade, A., Oza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R., Choodari-Oskooei, B., Powles, T., Stewart, G., Albiges, L., Stockler, M., et al (2021). RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemporary Clinical Trials, 108, 106481. [More Information]
- Oza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R., Choodari-Oskooei, B., Powles, T., Stewart, G., Albiges, L., Bex, A., Stockler, M., et al (2021). RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemporary Clinical Trials, 108, 106482. [More Information]
- Lin, H., Yeung, N., Hastings, J., Croucher, D., Huynh, K., Meikle, T., Mellett, N., Kwan, E., Davis, I., Tran, B., Mahon, K., Zhang, A., Stockler, M., Horvath, L., et al (2021). Relationship between circulating lipids and cytokines in metastatic castration-resistant prostate cancer. Cancers, 13(19), 4964. [More Information]
- Livingstone (nee Ratcliffe), A., Milne, D., Dempsey, K., Muscat, D., Menzies, A., Howard, K., Stockler, M., Morton, R. (2021). Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. The Patient, 14(5), 635-647. [More Information]
- Ranganathan, P., Chinnaswamy, G., Sengar, M., Gadgil, D., Thiagarajan, S., Bhargava, B., Booth, C., Buyse, M., Chopra, S., Frampton, C., Stockler, M., et al (2021). The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. The Lancet Oncology, 22(8), e369-e376. [More Information]
2020
- Eisen, T., Frangou, E., Oza, B., Ritchie, A., Smith, B., Kaplan, R., Davis, I., Stockler, M., Albiges, L., Escudier, B., et al (2020). Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: Results from the SORCE randomized phase III intergroup trial. Journal of Clinical Oncology, 38(34), 4064-4075. [More Information]
- Stockler, M. (2020). ASCO updated recommendations for preventing and treating VTE in adults with cancer. Annals of Internal Medicine, 172(2), JC2. [More Information]
- Vasista, A., Stockler, M., Martin, A., Lawrence, N., Kiely, B. (2020). Communicating prognostic information: what do oncologists think patients with incurable cancer should be told? Internal Medicine Journal, 50(12), 1492-1499. [More Information]
- Nowak, A., Lesterhuis, W., Kok, P., Brown, C., Hughes, B., Karikios, D., John, T., Kao, S., Leslie, C., Cook, A., Langford, A., Yip, S., Stockler, M., et al (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21(9), 1213-1223. [More Information]
- Sridhar, S., Blais, N., Tran, B., Reaume, M., North, S., Stockler, M., Chi, K., Fleshner, N., Liu, G., Robinson, J., et al (2020). Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients with Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. JAMA Oncology, 6(11), 1751-1758. [More Information]
- Smith-Uffen, M., Johnson, S., Martin, A., Tattersall, M., Stockler, M., Bell, M., Detering, K., Clayton, J., Silvester, W., Clarke, S., Vaccaro, L., Beale, P., Kiely, B. (2020). Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. Supportive Care in Cancer, 28(7), 3399-3407. [More Information]
- Moth, E., Blinman, P., Stefanic, N., Naganathan, V., Grimison, P., Stockler, M., Beale, P., Martin, A., Kiely, B. (2020). Estimating survival time in older adults receiving chemotherapy for advanced cancer. Journal of Geriatric Oncology, 11(4), 617-625. [More Information]
- Cohen, P., Leung, Y., Anderson, L., Van Der Griend, R., Chivers, P., Bilic, S., Bittinger, S., Brand, A., Bulsara, M., Codde, J., Stockler, M., et al (2020). Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy. Gynecologic Oncology, 159(3), 623-629. [More Information]
- Lawrence, N., Martin, A., Davis, I., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Smith, B., Ritchie, A., Stockler, M., et al (2020). Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 4(4), 185-195. [More Information]
- Grimison, P., Mersiades, T., Kirby, A., Lintzeris, N., Morton, R., Haber, P., Olver, I., Walsh, A., McGregor, I., Cheung, Y., Simes, R., Stockler, M., et al (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology, 31(11), 1553-1560. [More Information]
- Mercieca-Bebber, R., Stockler, M. (2020). Patient-reported outcomes and localized prostate cancer management. Nature Reviews Urology, 17(5), 257-258. [More Information]
- Scheinberg, T., Kench, J., Stockler, M., Mahon, K., Sebastian, L., Stricker, P., Joshua, A., Woo, H., Thanigasalam, R., Ahmadi, N., Horvath, L., et al (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), e033667. [More Information]
- Roncolato, F., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Salutari, V., Donnellan, P., Stockler, M., King, M., et al (2020). Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>= 3) chemotherapy - The GCIG symptom benefit study (SBS). Gynecologic Oncology, 156(1), 45-53. [More Information]
- Livingstone (nee Ratcliffe), A., Agarwal, A., Stockler, M., Menzies, A., Howard, K., Morton, R. (2020). Preferences for Immunotherapy in Melanoma: A Systematic Review. Annals of Surgical Oncology, 27(2), 571-584. [More Information]
- Vasista, A., Ryan, L., Naher, S., Moylan, E., Stockler, M., Wilcken, N., Kiely, B. (2020). Survival and cardiac toxicity in patients with HER2-positive, metastatic breast cancer treated with trastuzumab in routine clinical practice. Asia-Pacific Journal of Clinical Oncology, 16(1), 34-38. [More Information]
- Nowak, A., Findlay, M., Culjak, G., Stockler, M. (2020). Tamoxifen for hepatocellular carcinoma. Cochrane Database of Systematic Reviews, 2020 (8), CD001024. [More Information]
- Whitford, H., Kalinowski, P., Schembri, A., Grimison, P., Stockler, M., Martin, A., Toner, G., Davis, I., Maruff, P., Olver, I. (2020). The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. Supportive Care in Cancer, 28(7), 3081-3091. [More Information]
- Lee, K., Lord, S., Kasherman, L., Marschner, I., Stockler, M., Gralla, R., Yang, J., Mok, T., Lee, C. (2020). The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncologica, 59(1), 96-100. [More Information]
- Kiely, B., Stockler, M. (2020). When Should Oncologists Use the Words Hope and Cure? JNCI Cancer Spectrum, 4(6), pkaa066. [More Information]
2019
- Kiely, B., Stockler, M. (2019). Accentuating the Positive: Do Trials Give Unrealistic Expectations of Long-Term Survival? JNCI Cancer Spectrum, 3(2), 1-2. [More Information]
- Vasista, A., Stockler, M., Martin, A., Pavlakis, N., Sjoquist, K., Goldstein, D., Gill, S., Jain, V., Liu, G., Kannourakis, G., Kiely, B., et al (2019). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. The Oncologist, 24(11), e1102-e1107. [More Information]
- Chim, L., Salkeld, G., Kelly, P., Lipworth, W., Hughes, D., Stockler, M. (2019). Community views on factors affecting medicines resource allocation: Cross-sectional survey of 3080 adults in Australia. Australian Health Review, 43(3), 254-260. [More Information]
- Kiely, B., Stockler, M. (2019). Discussing Prognosis, Preferences, and End-of-Life Care in Advanced Cancer: We Need to Speak. JAMA Oncology, 5(6), 788-789. [More Information]
- Davis, I., Stockler, M., Sweeney, C. (2019). Enzalutamide in Metastatic Prostate Cancer Reply. New England Journal of Medicine, 381(15), 1494-1495. [More Information]
- Davis, I., Martin, A., Stockler, M., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Horvath, L., Marx, G., Tu, E., Yip, S., Zhang, A., et al (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131. [More Information]
- Mersiades, T., Stockler, M., Olver, I., Grimison, P. (2019). Medicinal cannabis for chemotherapy-induced nausea and vomiting: prescribing with limited evidence. Medical Journal of Australia, 210(1), 11-1.20E+02. [More Information]
- Moth, E., Kiely, B., Stefanic, N., Naganathan, V., Martin, A., Grimison, P., Stockler, M., Beale, P., Blinman, P. (2019). Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. Journal of Geriatric Oncology, 10(2), 210-215. [More Information]
- Morgans, A., Stockler, M. (2019). Patient-reported Outcomes in Metastatic Castration-sensitive Prostate Cancer in the Adjuvant Setting. European Urology Focus, 5(2), 144-146. [More Information]
- Lindemann, K., Beale, P., Rossi, E., Goh, J., Vaughan, M., Tenney, M., Martyn, J., Sommeijer, D., Iglesias, J., Kremmidiotis, G., et al (2019). Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). Cancer Chemotherapy and Pharmacology, 83(1), 97-105. [More Information]
- Moth, E., Kiely, B., Stefanic, N., Naganathan, V., Martin, A., Grimison, P., Stockler, M., Beale, P., Blinman, P. (2019). Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. Journal of Geriatric Oncology, 10(2), 202-209. [More Information]
- Mahon, K., Qu, W., Lin, H., Spielman, C., Cain, D., Jacobs, C., Stockler, M., Higano, C., de Bono, J., Chi, K., Horvath, L., et al (2019). Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. European Urology, 76(3), 306-312. [More Information]
- Hofman, M., Emmett, L., Violet, J., Zhang, A., Lawrence, N., Stockler, M., Francis, R., Iravani, A., Williams, S., Azad, A., Martin, A., et al (2019). TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU International, 124(S1), 5-13. [More Information]
2018
- Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Tattersall, M., et al (2018). A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. British Journal of Cancer, 119(10), 1182-1190. [More Information]
- Tran, A., Fogarty, G., Nowak, A., Espinoza, D., Rowbotham, N., Stockler, M., Morton, R. (2018). A systematic review and meta-analysis of utility estimates in melanoma. British Journal of Dermatology, 178(2), 384-393. [More Information]
- Smith, B., Rutherford, C., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G., Stockler, M., King, M. (2018). A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psycho-Oncology, 27(4), 1129-1137. [More Information]
- Zhang, A., Judson, I., Benson, C., Wunder, J., Ray-Coquard, I., Grimer, R., Quek, R., Wong, E., Miah, A., Ferguson, P., Stockler, M., Tattersall, M., et al (2018). Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. British Journal of Cancer, 117, 326-331. [More Information]
- Stockler, M., Wilcken, N., Coates, A., Ghersi, D. (2018). Duration of chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, 2018 (2). [More Information]
- Lawrence, N., Roncolato, F., Martin, A., Simes, R., Stockler, M. (2018). Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer. JNCI Cancer Spectrum, 2(4). [More Information]
- King, M., Stockler, M., O'Connell, R., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Bryce, J., Costa, D., et al (2018). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 27(1), 59-74. [More Information]
- Mersiades, T., Tognela, A., Haber, P., Stockler, M., Lintzeris, N., Simes, R., McGregor, I., Olver, I., Allsop, D., Gedye, C., Kirby, A., Morton, R., Wong, N., Walsh, A., Grimison, P., et al (2018). Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 8(9), 1-8. [More Information]
- Blinman, P., Davis, I., Martin, A., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., et al (2018). Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Annals of Oncology, 29(2), 370-376. [More Information]
- Stockler, M. (2018). Pooled RCTs: Reanalysis accounting for screening intensity suggests that screening reduces prostate cancer mortality. Annals of Internal Medicine, 168(2), JC5. [More Information]
- Lawrence, N., Chan, H., Toner, G., Stockler, M., Martin, A., Yip, S., Wong, N., Yeung, A., Mazhar, D., Pashankar, F., et al (2018). Protocol for the P3BEP trial (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer, 18(1), 1-6. [More Information]
- Wong, S., North, S., Sweeney, C., Stockler, M., Sridhar, S. (2018). Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 16(1), e233-e242. [More Information]
- Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., Simes, R., Stockler, M., Morton, R. (2018). Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics, 36(1), 67-78. [More Information]
- Mercieca-Bebber, R., Calvert, M., Kyte, D., Stockler, M., King, M. (2018). The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. Contemporary Clinical Trials Communications, 9, 23-32. [More Information]
- Mercieca-Bebber, R., King, M., Calvert, M., Stockler, M., Friedlander, M. (2018). The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Measures, 9, 353-367. [More Information]
- Roncolato, F., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., Okamoto, A., Aotani, E., Lorusso, D., Donnellan, P., Stockler, M., King, M., et al (2018). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 148(1), 36-41. [More Information]
- Lawrence, N., Martin, A., Davis, I., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Smith, B., Ritchie, A., Stockler, M., et al (2018). What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. Kidney Cancer, 2(2), 123-131. [More Information]
2017
- Lin, H., Mahon, K., Weir, J., Mundra, P., Spielman, C., Briscoe, K., Gurney, H., Mallesara, G., Marx, G., Stockler, M., Hoy, A., Horvath, L., et al (2017). A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. International Journal of Cancer, 141(10), 2112-2120. [More Information]
- Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Beale, P., Fitzgerald, N., Tattersall, M. (2017). A Randomized Controlled Trial of an Advance Care Planning Intervention for Patients with Incurable Cancer. The 44th Clinical Oncological Society of Australia Annual Scientific Meeting,.
- Mercieca-Bebber, R., Friedlander, M., Calvert, M., Stockler, M., Kyte, D., Kok, P., King, M. (2017). A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. Journal of Patient-Reported Outcomes, 1, 1-10. [More Information]
- Sundaresan, P., King, M., Stockler, M., Costa, D., Milross, C. (2017). Barriers to radiotherapy utilization: Consumer perceptions of issues influencing radiotherapy-related decisions. Asia-Pacific Journal of Clinical Oncology, 13(5), e489-e496. [More Information]
- Hayne, D., Stockler, M., McCombie, S., Lawrence, N., Martin, A., Sengupta, S., Davis, I. (2017). BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned. BJU International, 119, 55-57. [More Information]
- O'Carrigan, B., Wong, M., Willson, M., Stockler, M., Pavlakis, N., Goodwin, A. (2017). Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews, 2017 (10), 1-210. [More Information]
- Zhang, A., Judson, I., Benson, C., Wunder, J., Ray-Coquard, I., Grimer, R., Quek, R., Wong, E., Miah, A., Ferguson, P., Stockler, M., Tattersall, M., et al (2017). Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. British Journal of Cancer, 117, 326-331. [More Information]
- Karikios, D., Mileshkin, L., Martin, A., Ferraro, D., Stockler, M. (2017). Discussing and prescribing expensive unfunded anticancer drugs in Australia. ESMO Open, 2(2), 1-7. [More Information]
- Butow, P., Tattersall, M., Stockler, M. (2017). Discussing prognosis and communicating risk. In D. Kissane, B. Bultz, P. Butow, C. Bylund, S. Noble & S. Wilkinson (Eds.), Oxford Textbook of Communication in Oncology and Palliative Care (Second Edition), (pp. 77-82). Oxford: Oxford University Press. [More Information]
- Heiniger, L., Smith, B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J., Price, M., McJannett, M., Tran, B., Stockler, M., Gurney, H., Butow, P. (2017). e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer. European Journal of Cancer Care, 26(6), e12698. [More Information]
- Lindemann, K., Kok, P., Stockler, M., Jaaback, K., Brand, A. (2017). Enhanced recovery after surgery for advanced ovarian cancer: A systematic review of interventions trialed. International Journal of Gynecological Cancer, 27(6), 1274-1282. [More Information]
- Lindemann, K., Kok, P., Stockler, M., Sykes, P., Brand, A. (2017). Enhanced recovery after surgery for suspected ovarian malignancy: A survey of perioperative practice among gynecologic oncologists in Australia and New Zealand to Inform a Clinical Trial. International Journal of Gynecological Cancer, 27(5), 1046-1050. [More Information]
- Mercieca-Bebber, R., Friedlander, M., Kok, P., Calvert, M., Kyte, D., Stockler, M., King, M. (2017). Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. Quality of Life Research, 26(8), 2249-2250. [More Information]
- Cohen, P., Brand, A., Sykes, P., Wrede, D., McNally, O., Eva, L., Rao, A., Campion, M., Stockler, M., Powell, A., et al (2017). Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open, 7(8), 1-9. [More Information]
- Duchesne, G., Woo, H., King, M., Bowe, S., Stockler, M., Ames, A., D’Este, C., Frydenberg, M., Loblaw, A., Malone, S., Turner, S., et al (2017). Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. The Lancet Oncology, 18(9), 1192-1201. [More Information]
- Karikios, D., Chim, L., Martin, A., Nagrial, A., Howard, K., Salkeld, G., Stockler, M. (2017). Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia. Internal Medicine Journal, 47(4), 400-407. [More Information]
- Chambers, S., Occhipinti, S., Foley, E., Clutton, S., Legg, M., Berry, M., Stockler, M., Frydenberg, M., Gardiner, R., Lepore, S., Smith, D., et al (2017). Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 35(3), 291-297. [More Information]
- Vasista, A., Stockler, M., West, T., Wilcken, N., Kiely, B. (2017). More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. The Breast, 31, 99-104. [More Information]
- Lin, H., Mahon, K., Spielman, C., Gurney, H., Mallesara, G., Stockler, M., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A., Horvath, L. (2017). Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 116(8), 1002-1011. [More Information]
- Roncolato, F., Gibbs, E., Lee, C., Asher, R., Davies, L., Gebski, V., Friedlander, M., Hilpert, F., Wenzel, L., Stockler, M., King, M., et al (2017). Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Annals of Oncology, 28(8), 1849-1855. [More Information]
- Roncolato, F., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Stockler, M., King, M., et al (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. The Oncologist, 22(9), 1117-1124. [More Information]
- Wetzig, N., Gill, P., Espinoza, D., Mister, R., Stockler, M., Gebski, V., Ung, O., Campbell, I., Simes, R. (2017). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. Annals of Surgical Oncology, 24(4), 1064-1070. [More Information]
- Chim, L., Salkeld, G., Kelly, P., Lipworth, W., Hughes, D., Stockler, M. (2017). Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. PloS One, 12(3), 1-24. [More Information]
2016
- Johnson, S., Clayton, J., Butow, P., Silvester, W., Detering, K., Hall, J., Kiely, B., Cebon, J., Clarke, S., Bell, M., Stockler, M., Tattersall, M., et al (2016). Advance care planning in patients with incurable cancer: Study protocol for a randomised controlled trial. BMJ Open, 6(12), 1-10. [More Information]
- Dong, S., Butow, P., Agar, M., Lovell, M., Boyle, F., Stockler, M., Forster, B., Jaure, A. (2016). Clinicians' Perspectives on Managing Symptom Clusters in Advanced Cancer: A Semistructured Interview Study. Journal of Pain and Symptom Management, 51(4), 706-717.e5. [More Information]
- Mercieca-Bebber, R., Palmer, M., Brundage, M., Calvert, M., Stockler, M., King, M. (2016). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. BMJ Open, 6(6), 1-47. [More Information]
- Schofield, P., Stockler, M., Zannino, D., Tebbutt, N., Price, T., Simes, R., Wong, N., Pavlakis, N., Ransom, D., Moylan, E., Wilcken, N., et al (2016). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Supportive Care in Cancer, 24(1), 401-408. [More Information]
- Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Grimison, P., et al (2016). Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 27(12), 2302-2303. [More Information]
- Blinman, P., Mileshkin, L., Khaw, P., Goss, G., Johnson, C., Capp, A., Brooks, S., Wain, G., Kolodziej, I., Veillard, A., O'Connell, R., Stockler, M., et al (2016). Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115(10), 1179-1185. [More Information]
- Dong, S., Butow, P., Jaure, A., Agar, M., Boyle, F., Forster, B., Stockler, M., Lovell, M. (2016). Patients' experiences and perspectives of multiple concurrent symptoms in advanced cancer: a semi-structured interview study. Supportive Care in Cancer, 24(3), 1373-1386. [More Information]
- Moth, E., McLachlan, S., Veillard, A., Muljadi, N., Hudson, M., Stockler, M., Blinman, P. (2016). Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer. Lung Cancer, 95, 8-14. [More Information]
- Sundaresan, P., Milross, C., Stockler, M., Costa, D., King, M. (2016). Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issues. Quality of Life Research, 25(9), 2361-2366. [More Information]
- Roncolato, F., Chatfield, M., Houghton, B., Toner, G., Stockler, M., Thomson, D., Friedlander, M., Gurney, H., Rosenthal, M., Grimison, P. (2016). The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal, 46(8), 893-898. [More Information]
- Mercieca-Bebber, R., Friedlander, M., Kok, P., Calvert, M., Kyte, D., Stockler, M., King, M. (2016). The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (with Erratum). Quality of Life Research, 25(10), 2457-2465. [More Information]
- Smith, B., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Turner, S., Gurney, H., King, M., et al (2016). The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship, 10(2), 223-233. [More Information]
- Chambers, S., Foley, E., Clutton, S., McDowall, R., Occhipinti, S., Berry, M., Stockler, M., Lepore, S., Frydenberg, M., Gardiner, R., et al (2016). The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Quality of Life Research, 25(12), 3027-3035. [More Information]
- Duchesne, G., Woo, H., Bassett, J., Bowe, S., D'Este, C., Frydenberg, M., King, M., Ledwich, L., Loblaw, A., Malone, S., Stockler, M., et al (2016). Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. The Lancet Oncology, 17(6), 727-737. [More Information]
- Lawrence, N., Salkeld, G., Stockler, M., Karikios, D. (2016). Valuing the benefits of new anticancer drugs. Medical Journal of Australia, 204(11), 403-405. [More Information]
- Sundaresan, P., Stockler, M., Milross, C. (2016). What is access to radiation therapy? A conceptual framework and review of influencing factors. Australian Health Review, 40(1), 11-18. [More Information]
2015
- Davidson, A., Veillard, A., Tognela, A., Chan, M., Huighes, B., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Chinchen, S., Espinoza, D., Coskinas, X., Pavlakis, N., Stockler, M., et al (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Annals of Oncology, 26(11), 2280-2286. [More Information]
- Sundaresan, P., King, M., Stockler, M., Costa, D., Milross, C. (2015). Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors. Journal of Medical Imaging and Radiation Oncology, 59(4), 535-541. [More Information]
- Hayne, D., Stockler, M., McCombie, S., Chalasani, V., Long, A., Martin, A., Sengupta, S., Davis, I. (2015). BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC Cancer, 15(1), 1-7. [More Information]
- Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British Journal of Cancer, 112(8), 1340-1348. [More Information]
- Juraskova, I., Butow, P., Fisher, A., Bonner, C., Anderson, C., Bu, S., Scarlet, J., Stockler, M., Wetzig, N., Ung, O., et al (2015). Development and piloting of a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 breast cancer trial. Clinical Trials, 12(4), 409-417. [More Information]
- Moth, E., Parry, J., Stockler, M., Beale, P., Blinman, P., Della Fiorentina, S., Kiely, B. (2015). Doctor to doctor communication of prognosis in metastatic cancer: a review of letters from medical oncologists to referring doctors. Internal Medicine Journal, 45(9), 909-915. [More Information]
- Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
- Elmadahm, A., Gill, P., Bochner, M., Gebski, V., Zannino, D., Wetzig, N., Campbell, I., Stockler, M., Ung, O., Simes, R., Uren, R. (2015). Identification of the sentinel lymph node in the SNAC-1 trial. ANZ Journal of Surgery, 85(1-2), 58-63. [More Information]
- Stockler, M. (2015). In palliative care, discontinuation of statins did not differ from continuation for mortality. Annals of Internal Medicine, 163(4), JC7-JC7. [More Information]
- Blinman, P., Hughes, B., Crombie, C., Christmas, T., Hudson, M., Veillard, A., Muljadi, N., Millward, M., Wright, G., Flynn, P., Stockler, M., et al (2015). Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile? European Journal of Cancer, 51(12), 1529-1537. [More Information]
- Sundaresan, P., Sullivan, L., Pendlebury, S., Kirby, A., Rodger, A., Joseph, D., Campbell, I., Dhillon, H., Stockler, M. (2015). Patients' Perceptions of Health-related Quality of Life During and After Adjuvant Radiotherapy for T1N0M0 Breast Cancer. Clinical Oncology, 27(1), 9-15. [More Information]
- Lyerley, H., Fawzy, M., Aziz, Z., Nair, R., Pramesh, C., Parmar, V., Parikh, P., Jamal, R., Irumnaz, A., Ren, J., Stockler, M., et al (2015). Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. The Oncologist, 20(5), 1-7. [More Information]
- Wetzig, N., Gill, P., Zannino, D., Stockler, M., Gebski, V., Ung, O., Campbell, I., Simes, R. (2015). Sentinel Lymph Node Based Management or Routine Axillary Clearance? Three-year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial. Annals of Surgical Oncology, 22(1), 17-23. [More Information]
- Sengupta, S., Grimison, P., Hayne, D., Williams, S., Chambers, S., de Souza, P., Stockler, M., McJannett, M., Toner, G., Davis, I. (2015). The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group - a new co-operative cancer trials group in genitourinary oncology. BJU International, 115(6), 856-858. [More Information]
- Chim, L., Salkeld, G., Stockler, M., Mileshkin, L. (2015). Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists. Internal Medicine Journal, 45(8), 834-842. [More Information]
2014
- Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
- Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
- Ellis, P., Shepherd, F., Millward, M., Perrone, F., Seymour, L., Liu, G., Sun, S., Cho, B., Morabito, A., Leighl, N., Stockler, M., et al (2014). Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. The Lancet Oncology, 15(12), 1379-1388. [More Information]
- King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
- Tattersall, M., Martin, A., Devine, R., Ryan, J., Jansen, J., Hastings, L., Boyer, M., Glare, P., Stockler, M., Butow, P. (2014). Early Contact with Palliative Care Services: A Randomized Trial in Patients with Newly Detected Incurable Metastatic Cancer. Journal of Palliative Care & Medicine, 4(1), 1-6. [More Information]
- West, T., Kiely, B., Stockler, M. (2014). Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 50(11), 1916-1924. [More Information]
- Sundaresan, P., Milross, C., Smith, A., Evans, A., Stockler, M., King, M. (2014). Factors influencing the use of RT in NSW: A qualitative study exploring consumer and health professional perspectives. Journal of Medical Imaging and Radiation Oncology, 58(5), 625-632. [More Information]
- Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
- Goodwin, P., Bruera, E., Stockler, M. (2014). Pain in patients with cancer. Journal of Clinical Oncology, 32(16), 1637-1639. [More Information]
- Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1319. [More Information]
- Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Stockler, M., et al (2014). Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer, 50(4), 706-712. [More Information]
- Karikios, D., Schofield, D., Salkeld, G., Robledo, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
- Beumer, J., Gill, G., Campbell, I., Wetzig, N., Ung, O., Farshid, G., Uren, R., Stockler, M., Gebski, V. (2014). Sentinel node biopsy and large (3cm) breast cancer. ANZ Journal of Surgery, 84(3), 117-120. [More Information]
- Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]
- O'Carrigan, B., Fournier, M., Olver, I., Stockler, M., Whitford, H., Toner, G., Thomson, D., Davis, I., Hanning, F., Singhal, N., McDonald, A., Boland, A., Grimison, P., et al (2014). Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. Internal Medicine Journal, 44(8), 813-817. [More Information]
2013
- Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
- McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
- Gzell, C., Kench, J., Stockler, M., Hruby, G. (2013). Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. International Urology and Nephrology, 45(3), 735-742. [More Information]
- Pavlakis, N., Patel, D., Stockler, M. (2013). Bisphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 2013 (6). [More Information]
- Friedlander, M., Stockler, M., Butow, P., King, M., McAlpine, J., Tinker, A., Ledermann, J. (2013). Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? Journal of Clinical Oncology, 31(18), 2362. [More Information]
- Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
- Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
- Stockler, M. (2013). Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Annals of Internal Medicine, 158(2), JC9. [More Information]
- Houghton, B., Chalasani, V., Hayne, D., Grimison, P., Brown, C., Patel, M., Davis, I., Stockler, M. (2013). Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 111(6), 977-933. [More Information]
- Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine, 16(8), 938-940. [More Information]
- Grimison, P., Houghton, B., Chatfield, M., Toner, G., Davis, I., Martin, J., Hovey, E., Stockler, M. (2013). Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 112(2), E35-E43. [More Information]
- Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
- Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
- Martin, A., Lord, S., Carter, H., Stockler, M., Emery, J. (2013). Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Medical Journal of Australia, 198(10), 546-550. [More Information]
- Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., et al (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology, 14(3), 236-243. [More Information]
- Thientosapol, E., Tran, T., Della Fiorentina, S., Adams, D., Chantrill, L., Stockler, M., Kiely, B. (2013). Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Internal Medicine Journal, 43(8), 883-888. [More Information]
- Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
- Smith, B., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology, 22(11), 2557-2564. [More Information]
- Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]
2012
- Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
- Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
- Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444. [More Information]
- Kiely, B., Stockler, M. (2012). Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine, 156(6), JC3-4-JC3-4. [More Information]
- Blinman, P., King, M., Norman, R., Viney, R., Stockler, M. (2012). Preferences for cancer treatments: An overview of methods and applications in oncology. Annals of Oncology, 23(5), 1104-1110. [More Information]
- King, M., Viney, R., Smith, D., Hossain, I., Street, D., Savage, E., Fowler, S., Berry, M., Stockler, M., Cozzi, P., Armstrong, B., et al (2012). Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 106(4), 638-645. [More Information]
- Stockler, M., Wilcken, N. (2012). Why Is Management of Cancer Pain Still a Problem? Journal of Clinical Oncology, 30(16), 1907-1908. [More Information]
2011
- Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
- Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
- Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]
- Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2011). How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 29(4), 456-463. [More Information]
- Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
- Blinman, P., McLachlan, S., Nowak, A., Duric, V., Brown, C., Wright, G., Millward, M., Fong, K., Stockler, M. (2011). Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), 213-218. [More Information]
- Lyerly, H., Abernethy, A., Stockler, M., Koczwara, B., Aziz, Z., Nair, R., Seymour, L. (2011). Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice, 7(5), 324-329. [More Information]
- Chen, J., Hruby, G., Stockler, M., Patanjali, N., Bucci, J., Perez, G., Loadsman, J., Sheehan, E. (2011). Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy, 10(6), 454-460. [More Information]
- Hruby, G., Chen, J., Bucci, J., Loadsman, J., Perry, P., Stockler, M. (2011). Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy, 10(5), 395-400. [More Information]
- Stockler, M. (2011). Quality of Life and Targeted Treatment for Metastatic Renal Cell Carcinoma. The Oncologist, 16(8), 1070-1071. [More Information]
- Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
- Ooi, W., Stockler, M., Hayne, D. (2011). Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993). European Urology, 60(1), e1-e8. [More Information]
- Kiely, B., Stockler, M., Tattersall, M. (2011). Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology, 38(3), 380-385. [More Information]
2010
- Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
- Lovell, M., Forder, P., Stockler, M., Butow, P., Briganti, E., Chye, R., Goldstein, D., Boyle, F. (2010). A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. Journal of Pain and Symptom Management, 40(1), 49-59. [More Information]
- Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
- Chim, L., Kelly, P., Salkeld, G., Stockler, M. (2010). Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? PharmacoEconomics, 28(6), 463-475. [More Information]
- Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
- Kiely, B., Tattersall, M., Stockler, M. (2010). Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. Journal of Clinical Oncology, 28(16), 2802-2804. [More Information]
- Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
- Liu, S., Stockler, M., Lin, B. (2010). Five-Year Survival After Multimodal Approach in a Patient With Muscle-Invasive Transitional Cell Carcinoma of the Bladder and Adrenal Metastasis. UroToday International Journal, 3(5), 0.
- Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
- Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
- Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Chapman, S., Barratt, A., Stockler, M. (2010). Let sleeping dogs lie What men should know before getting tested for prostate cancer. Sydney: Sydney University Press.
- King, M., Stockler, M., Cella, D., Osoba, D., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. Journal of Clinical Epidemiology, 63(3), 270-281. [More Information]
- King, M., Cella, D., Osoba, D., Stockler, M., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Related Outcome Measures, 1, 119-126. [More Information]
- Blinman, P., Alam, M., Duric, V., McLachlan, S., Stockler, M. (2010). Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review. Lung Cancer, 69(2), 141-147. [More Information]
- Luckett, T., King, M., Stockler, M. (2010). Quality of life research in prostate and testicular cancer. Cancer Forum, 34(1), 20-23. [More Information]
- Tebbutt, N., Parry, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481. [More Information]
- Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
2009
- Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
- Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
- Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
- Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. Value in Health, 12(6), 967-976. [More Information]
- Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
- Barratt, A., Stockler, M. (2009). Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 191(4), 226-229. [More Information]
- Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
- Stockler, M., March, L., Lindley, R., Mellis, C. (2009). Students' PEARLS: successfully incorporating evidence-based medicine in medical students' clinical attachments. Annals of Internal Medicine, 150(8), JC4-2-JC4-3. [More Information]
- Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]
- Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N. (2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 20(11), 1771-1785. [More Information]
- Greaves, J., Glare, P., Kristjanson, L., Stockler, M., Tattersall, M. (2009). Undertreatment of nausea and other symptoms in hospitalized cancer patients. Supportive Care in Cancer, 17(4), 461-464. [More Information]
2008
- Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67. [More Information]
- Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, 117(1), 99-109. [More Information]
- Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
- Butow, P., Hagerty, R., Tattersall, M., Stockler, M. (2008). Foretelling: Communicating the prognosis. In N. Christakis and P. Glare (Eds.), Prognosis in Advanced Cancer, (pp. 33-53). Oxford: Oxford University Press.
- Gainford, M., Yang, C., Liu, M., Stockler, M. (2008). Translation and cultural adaptation of the patient disease and treatment assessment form: A novel quality of life instrument for use in Taiwan. Asia-Pacific Journal of Clinical Oncology, 4(3), 149-156. [More Information]
- Lee, B., King, M., Simpson, J., Haran, M., Stockler, M., Marial, O., Salkeld, G. (2008). Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population. Value in Health, 11(4), 680-688. [More Information]
2007
- Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
- Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
- Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8(7), 603-612. [More Information]
- Wilcken, N., Stockler, M. (2007). Ovarian suppression for early breast cancer. The Lancet, 369, 1668-1670. [More Information]
- Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology, 16(1), 48-59. [More Information]
- Grimison, P., Stockler, M. (2007). Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy, 7(8), 1123-1134. [More Information]
- Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N., et al (2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 18(2), 215-225. [More Information]
2006
- Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
- Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
- Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
- Stockler, M., Duric, V., Coates, A. (2006). Patients' preferences: what makes treatments worthwhile? In Martine J. Piccart .. [et al.] (Eds.), Breast cancer and molecular medicine, (pp. 925-944). Berlin ; New York: Springer.
- Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
- Hauser, C., Stockler, M., Tattersall, M. (2006). Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supportive Care in Cancer, 14, 999-1011. [More Information]
- Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
- Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
- Stockler, M., Heritier, S., Nowak, A., Goldstein, D., Turner, J., Jefford, M., Glasgow, A., Abdi, E., Beale, P., Carter, C. (2006). The time taken to complete quality of life questionnaires in an advanced cancer trial. Journal of Clinical Oncology, 24(18S), 491s-491s.
2005
- Koczwara, B., Tattersall, M., Barton, M., Coventry, B., Dewar, J., Millar, J., Olver, I., Schwarz, M., Starmer, D., Turner, D., Stockler, M. (2005). Achieving equal standards in medical student education: is a national exit examination the answer? Medical Journal of Australia, 182(5), 228-230. [More Information]
- Joshua, A., Celermajer, D., Stockler, M. (2005). Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. Internal Medicine Journal, 35(3), 178-187. [More Information]
- Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 0(3), CD003474. [More Information]
- Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
- Haran, M., Lee, B., King, M., Marial, O., Stockler, M. (2005). Health status rated with the Medical Outcomes Study 36-Item Short-Form Health Survey after spinal cord injury. Archives of Physical Medicine and Rehabilitation, 86(12), 2290-2295. [More Information]
- Medd, J., Stockler, M., Collins, R., Lalak, A. (2005). Measuring men's opinions of prostate needle biopsy. ANZ Journal of Surgery, 75(8), 662-664. [More Information]
- Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillett, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2005). Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ Journal of Surgery, 75(3), 98-100. [More Information]
- Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
- Duric, V., Fallowfield, L., Saunders, C., Houghton, J., Coates, A., Stockler, M. (2005). Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? British Journal of Cancer, 93(12), 1319-1323. [More Information]
- Stockler, M. (2005). Review: bisphosphonates are modestly better than placebo for relieving painful bone metastases. ACP Journal Club, 143(1), 13. [More Information]
- Nowak, A., Stockler, M., Chow, P., Findlay, M. (2005). Use of Tamoxifen in Advanced-Stage Hepatocellular Carcinoma. Cancer, 103(7), 1408-1414. [More Information]
- Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
- Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
- Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? The Lancet Oncology, 6(8), 581-588. [More Information]
2004
- Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
- Stockler, M., Vardy, J., Pillai, A., Warr, D. (2004). Acetaminophen (Paracetamol) Improves Pain And Well-Being In People With Advanced Cancer Already Receiving A Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial. Journal of Clinical Oncology, 22(16), 3389-3394. [More Information]
- Nowak, A., Stockler, M., Byrne, M. (2004). Assessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172-3180. [More Information]
- Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049. [More Information]
- Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology, 22(14S), 73S-73S.
- Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71. [More Information]
- Nowak, A., Wilcken, N., Stockler, M., Hamilton, A., Ghersi, D. (2004). Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer. The Lancet Oncology, 5(6), 372-380. [More Information]
- Glare, P., Pereira, G., Kristjanson, L., Stockler, M., Tattersall, M. (2004). Systematic Review Of The Efficacy Of Antiemetics In The Treatment Of Nausea In Patients With Far-Advanced Cancer. Supportive Care in Cancer, 12(6), 432-440. [More Information]
2003
- Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.
- Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
- Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.
- Wilcken, N., Stockler, M. (2003). Fulvestrant: spreading the word, but not too thinly. The Lancet, 362(9392), 1254-1254. [More Information]
- Jefford, M., Stockler, M., Tattersall, M. (2003). Outcomes research: what is it and why does it matter? Internal Medicine Journal, 33(3), 110-118. [More Information]
- Eckermann, S., Martin, A., Stockler, M., Simes, R. (2003). The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 27(1), 34-40. [More Information]
2002
- Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17. [More Information]
- Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.
- Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.
- Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83. [More Information]
2001
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Craig, J., Irwig, L., Stockler, M., Barratt, A., Cumming, R., Caplehorn, J. (2001). Clinical epidemiology education: to help culture change now and generate new research later. 4th International Conference on the Scientific Basis of Health Services.
- Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745. [More Information]
- Craig, J., Irwig, L., Stockler, M. (2001). Evidence-based medicine: useful tools for decision making. Medical Journal of Australia, 174, 248-253.
- Gooden, B., Smith, M., Tattersall, S., Stockler, M. (2001). Hospitalised patients' views on doctors and white coats. Medical Journal of Australia, 175, 219-222.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Duric, V., Stockler, M. (2001). Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile? The Lancet Oncology, 2(11), 691-697. [More Information]
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
- Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
2000
- Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168. [More Information]
Selected Grants
2024
- P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours - An Australian-Led, International Randomised Trial, Grimison P, Stockler M, Martin A, National Health and Medical Research Council (NHMRC)/Clinical Trials and Cohort Studies
2022
- Clinical development of a self-amplifying pan-tumour theranostic, Hogg P, Simes R, Codd R, Scott A, Barrington S, Stockler M, Ho Shon I, Gebski V, Goldstein D, Thompson S, Cancer Institute NSW/Translational Program Grant
2021
- The ECHO trial: A randomised, controlled trial evaluating the effect of exercise during chemotherapy for ovarian cancer on survival and health resource use, Hayes S, Stockler M, Cancer Council Queensland/Research Grant
- The RACS SNAC2 Trial: A multicentre randomised controlled trial of sentinel node biopsy versus axillary clearance in operable breast cancer, Stockler M, Waikoto Breast Cancer Research Trust/Research Grant
- SNAC2 Study: multicentre randomised controlled trial of sentinel node biopsy versus axillary clearance in operable breast cancer, Stockler M, Royal Brisbane and Womens Hospital Foundation/Research Grant
2020
- Cancer Research Fund Initiatives (CRFI) - Martin Richard Stockler, Stockler M, DVC Research/CRFI-CRF White - Bequest
2019
- Oxtox: Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer - a phase II randomised study, Vardy J, Dhillon H, Stockler M, Clarke S, Australasian Gastro-Intestinal Trials Group/Research Support
2018
- Better Outcomes through Innovations in Clinical Trials: from Personalised Medicine to Population Health, Simes R, Keech A, Gebski V, Stockler M, Jenkins A, National Health and Medical Research Council (NHMRC)/Program Grants
- BCGMM Trial: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial, Hayne D, Stockler M, Frydenberg M, Martin A, Sengupta S, Patel M, Grummet J, Krieger L, McCombie S, National Health and Medical Research Council (NHMRC)/Project Grants
- Patient-reported outcomes and treatment preferences in 1,900 men with prostate cancer participating in two international, randomised clinical trials, Mercieca-Bebber R, Stockler M, National Health and Medical Research Council (NHMRC)/Early Career Fellowships
2017
- AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors, Yip S, Cook M, Stockler M, Yip D, Thomas D, Nowak A, Mitchell P, Antill Y, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2016
- Start-Up activities with or without a pilot and definitive randomised double-blind placebo-controlled trial or oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting, Grimison P, Haber P, Stockler M, Lintzeris N, Simes R, McGregor I, Olver I, Allsop D, Gedye C, Kirby A, NSW Health./Research Project Support
- The PEARL trial: Palliative care Early in Advanced Lung cancers, Mileshkin L, Yoong J, Nowak A, Stockler M, Philip J, Le B, Agar M, Phillips J, Goodall S, Schofield P, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2015
- Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy, Davis I, Grummet J, Chalasani V, Stockler M, Martin A, Hayne D, Woo H, Frydenberg M, O'Brien C, Buchan N, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2014
- OPTIMUM: Optimising Perioperative Therapy in Muscle invasive Urothelial Malignancy. A phase 3 trial of cisplatin and gemcitabine (CG) vs accelerated MVAC (accMVAC) given before or after cystectomy, Stockler M, DVC Research/Bridging Support Grant
2013
- Technical services of a genomic cancer clinical trial initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols, Stockler M, Simes R, Vachan B, Sjoquist K, Lee C, Yip S, Cancer Australia/Request for Tender
- Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial, Grimison P, Toner G, Stockler M, Friedlander M, Thomson D, Gebski V, King M, Quinn D, Singhal N, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
- Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial, Hayne D, Patel M, Stockler M, Sengupta S, Frydenberg M, Chalasani V, Gebski V, Davis I, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2012
- Advancing the evidence base for care and policy in priority health areas, Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner I, National Health and Medical Research Council (NHMRC)/Program Grants
- Cancer Institute NSW Cooperative Clinical Trial Grant for ANZUP, Grimison P, Stockler M, Woo H, Patel M, Hayden A, Sandoe D, Cancer Institute NSW/Cooperative Clinical Trial (CCT) Grants
- Development and operational support for the Australasian Lung Cancer Trials Group (ALTG) through the NHMRC Clinical Trial Centre: A NSW-led initiative, Pavlakis N, Boyer M, Stockler M, Dhillon H, Links M, Brown C, Lewis C, Stubbin I, Cancer Institute NSW/Cooperative Clinical Trial (CCT) Grants
- Development and operational support for ANZGOG through the NHMRC Clinical Trials Centre: A NSW lead initiative., Brand A, Friedlander M, Stockler M, Sjoquist K, Gebski V, Cancer Institute NSW/Cooperative Clinical Trial (CCT) Grants
- A pharmacodynamic study of the heat shock protein 90 Hsp90 inhibitor, AUY922, in high-risk, localised prostate cancer, Butler L, Horvath L, Tilley W, Stockler M, Stricker P, Kench J, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
- PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer, Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
- Evaluation of a web-based tool for estimating and explaining prognosis in advanced cancer, Kiely B, Stockler M, Butow P, Tattersall M, Simes R, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2011
- Using scenarios to estimate and explain survival time to people with incurable cancer, Kiely B, Stockler M, American Society of Clinical Oncology (USA)/Young Investigator Award
2010
- NITRO: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer, Davidson A, Millward M, Boyer M, Millward M, Fong K, McLachlan S, Singhal N, Stockler M, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
- START Trial: Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer, Millar J, Bolton D, Frydenberg M, Patel M, Williams S, Davis I, Stockler M, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2009
- Biostatistics, quality assurance and data systems for cancer trial groups activities based at the NHMRC Clinical Trials Centre, Gebski V, Simes R, Hague W, Gainford M, Stockler M, Goldstein D, Friedlander M, Grimison P, Cancer Institute NSW/Clinical Trials Infrastructure Grants
- Development and operational support for ALTG, ANZUP and GOGNO through the NHMRC Clinical Trials Centre: A NSW-led initiative, Stockler M, Simes R, Grimison P, Hague W, Cancer Institute NSW/Clinical Trials Infrastructure Grants
2008
- Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: What makes it worthwhile to patients and their doctors, McLachlan S, Duric V, Stockler M, Nowak A, Wright G, Boyer M, Hudson H, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
- Australian and New Zealand Germ Cell Trials Group (ANZGCTG), Toner G, Stockler M, Cancer Australia/Support for Cancer Clinical Trials
2007
- Clinical trials advances for better health outcomes, Simes R, Keech A, Gebski V, Stockler M, National Health and Medical Research Council (NHMRC)/Project Grants
- A randomised, phase III trial of adding nitroglycerin to first line chemotherapy in advanced non-small cell lung cancer, Davidson A, Boyer M, Stockler M, Cancer Council NSW/Research Project Grants
- Accelerated first line chemotherapy for advanced germ cell tumours, Friedlander M, Grimison P, Stockler M, Toner G, Cancer Council NSW/Research Project Grants
2005
- Strengthen Cancer Care initiative - Infrastructure Support for Clinical Trials Program (Psycho-Oncology Cooperative Research Group), Butow P, Dunn S, Girgis A, Kelly B, King M, King M, Mason C, Meiser B, Meiser B, Solomon M, Stockler M, Tattersall M, White K, Commonwealth Department of Health and Ageing/Strengthening Support For Cancer Care
- Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository, Keech A, Simes R, Gebski V, Hague W, Stockler M, National Health and Medical Research Council (NHMRC)/Enabling Grants
2004
- NSW psycho-oncology cooperative research group, Butow P, Dunn S, Girgis A, Kelly B, King M, King M, Mason C, Meiser B, Meiser B, Solomon M, Stockler M, Tattersall M, White K, Cancer Institute NSW/Research Grants Program - Category 3
- Infrastructure support for the AGITG and ANZGOG through the NHMRC Clinical Trials Centre - A NSW led initiative, Simes R, Stockler M, Cancer Institute NSW/Research Grant
- Sentinal node biopsy versus axillary clearence in breast cancer: the SNAC trial, Gebski V, Simes R, Stockler M, National Breast Cancer Foundation/Kathleen Cuningham Research Grant
2003
- The Zest Trial : a double-blind, placebo-controlled trial of Zolofts effects on symptoms and survival time in advanced cancer, Byrne M, Nowak A, Stockler M, Turner J, Wilken N, Wyld D, Cancer Council SA/Research Support
- The Zest Trial : a double-blind, placebo-controlled trial of Zolofts effects on symptoms and survival time in advanced cancer, Byrne M, Nowak A, Stockler M, Turner J, Wilken N, Wyld D, Cancer Council NSW/Research Project Grants
- A Phase II trial of gemcitabine in fixed dose rate infusion combined with cisplatin in patients with inoperable biliary tract carcinomas, Conley R, Goldstein D, Stockler M, Eli Lilly Australia Pty Ltd/Research Support
- A randomised phase II study evaluating a weekly schedule of Docetaxel (Taxotere R) with cisplatin and 5-FU (wTCF) or with Capecitabine (Xeloda R) (wTX) in advanced oesophago-gastric cancer., Conley R, Simes R, Stockler M, Australasian Gastro-Intestinal Trials Group./BLO Project
2002
- Sentinel node biopsy versus axillary clearance in early breast cancer: the SNAC Trial?, Collins J, Gill P, Wetzig N, Collins J, Ung O, Stockler M, National Health and Medical Research Council (NHMRC)/Clinical Trial Large Scale (CTLS)
- Advances in clinical trials research and evidence-based decision making, Gebski V, Keech A, Marschner I, Simes R, Stockler M, National Health and Medical Research Council (NHMRC)/Program Grants
- Not known, Stockler M, University of Sydney/Cancer Research Fund
2001
- Patient preferences for adjuvant chemotherapy for early breast cancer: what makes it worthwhile?, Coates A, Francis P, Reaby L, Simes R, Stockler M, National Health and Medical Research Council (NHMRC)/Project Grants
2000
- Antidepressants, well- being and survival in advanced cancer:The ZEST Trial., Stockler M, Pfizer Inc (USA)/BLO Project
- Antidepressants and subjective well-being in advanced cancer: a double-blind randomised trial of Sertraline and St Johns Wort, Simes R, Stockler M, Wilcken N, Cancer Council NSW/Research Project Grants
1999
- Provision of assessment and research related services on medical technologies and procedures for the Medical Services Advisory Committee (MSAC), Eckermann S, Eckermann S, Gebski V, Ghersi D, Howard K, Irwig L, Keech A, Lord S, Salkeld G, Simes R, Stockler M, Department of Health and Aged Care (Federal)/Research Support